U.S. patent number 11,358,977 [Application Number 16/614,015] was granted by the patent office on 2022-06-14 for deuterated pyridone amides and prodrugs thereof as modulators of sodium channels.
This patent grant is currently assigned to Vertex Pharmaceuticals Incorporated. The grantee listed for this patent is VERTEX PHARMACEUTICALS INCORPORATED. Invention is credited to Sara Sabina Hadida Ruah, Licong Jiang.
United States Patent |
11,358,977 |
Jiang , et al. |
June 14, 2022 |
Deuterated pyridone amides and prodrugs thereof as modulators of
sodium channels
Abstract
Compounds, and pharmaceutically acceptable salts thereof, useful
as inhibitors of sodium channels are provided. The compounds have
the formula (I) wherein R is H or CH.sub.2OPO(OH).sub.2. Also
provided are pharmaceutical compositions comprising the compounds
or pharmaceutically acceptable salts and methods of using the
compounds, pharmaceutically acceptable salts, and pharmaceutical
compositions in the treatment of various disorders, including pain.
##STR00001##
Inventors: |
Jiang; Licong (San Diego,
CA), Hadida Ruah; Sara Sabina (La Jolla, CA) |
Applicant: |
Name |
City |
State |
Country |
Type |
VERTEX PHARMACEUTICALS INCORPORATED |
Boston |
MA |
US |
|
|
Assignee: |
Vertex Pharmaceuticals
Incorporated (Boston, MA)
|
Family
ID: |
1000006370012 |
Appl.
No.: |
16/614,015 |
Filed: |
May 16, 2018 |
PCT
Filed: |
May 16, 2018 |
PCT No.: |
PCT/US2018/032939 |
371(c)(1),(2),(4) Date: |
November 15, 2019 |
PCT
Pub. No.: |
WO2018/213426 |
PCT
Pub. Date: |
November 22, 2018 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20210155643 A1 |
May 27, 2021 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
62507172 |
May 16, 2017 |
|
|
|
|
62547718 |
Aug 18, 2017 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07F
9/58 (20130101); C07B 59/002 (20130101); C07D
213/75 (20130101); C07B 2200/05 (20130101) |
Current International
Class: |
C07D
213/75 (20060101); C07F 9/58 (20060101); C07B
59/00 (20060101) |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
101855210 |
|
Oct 2010 |
|
CN |
|
101883758 |
|
Nov 2010 |
|
CN |
|
102264722 |
|
Nov 2011 |
|
CN |
|
103429571 |
|
Dec 2013 |
|
CN |
|
2003/034671 |
|
Feb 2003 |
|
JP |
|
2005/531501 |
|
Oct 2005 |
|
JP |
|
2011/500599 |
|
Jan 2011 |
|
JP |
|
2011/500600 |
|
Jan 2011 |
|
JP |
|
2012/506887 |
|
Mar 2012 |
|
JP |
|
2016/506963 |
|
Mar 2016 |
|
JP |
|
2016/508500 |
|
Mar 2016 |
|
JP |
|
2016/525122 |
|
Aug 2016 |
|
JP |
|
2010/118467 |
|
Nov 2011 |
|
RU |
|
2010/118481 |
|
Nov 2011 |
|
RU |
|
2013/31186 |
|
Aug 2013 |
|
TW |
|
WO 2002/008748 |
|
Jan 2002 |
|
WO |
|
WO 2003/068230 |
|
Aug 2003 |
|
WO |
|
WO 2005/013914 |
|
Feb 2005 |
|
WO |
|
WO 2006/011050 |
|
Feb 2006 |
|
WO |
|
WO 2007/120647 |
|
Oct 2007 |
|
WO |
|
WO 2008/135826 |
|
Nov 2008 |
|
WO |
|
WO 2009/049181 |
|
Apr 2009 |
|
WO |
|
WO 2009/049183 |
|
Apr 2009 |
|
WO |
|
WO 2010/072607 |
|
Jul 2010 |
|
WO |
|
WO 2010/137351 |
|
Dec 2010 |
|
WO |
|
WO 2011/026240 |
|
Mar 2011 |
|
WO |
|
WO 2011/140425 |
|
Nov 2011 |
|
WO |
|
WO 2012/106499 |
|
Aug 2012 |
|
WO |
|
WO 2012/112743 |
|
Aug 2012 |
|
WO |
|
WO 2012/116440 |
|
Sep 2012 |
|
WO |
|
WO 2012/119006 |
|
Sep 2012 |
|
WO |
|
WO 2012/125613 |
|
Sep 2012 |
|
WO |
|
WO 2013/061205 |
|
May 2013 |
|
WO |
|
WO 2013/109521 |
|
Jul 2013 |
|
WO |
|
WO 2013/114250 |
|
Aug 2013 |
|
WO |
|
WO 2013/131018 |
|
Sep 2013 |
|
WO |
|
WO 2013/132376 |
|
Sep 2013 |
|
WO |
|
WO 2014/120808 |
|
Aug 2014 |
|
WO |
|
WO 2014/120815 |
|
Aug 2014 |
|
WO |
|
WO 2014/120820 |
|
Aug 2014 |
|
WO |
|
WO 2015/010065 |
|
Jan 2015 |
|
WO |
|
WO 2015/089361 |
|
Jun 2015 |
|
WO |
|
Other References
Dyck et al., Journal of Neurochemistry vol. 46, Issue 2, pp.
399-404 (1986). (Year: 1986). cited by examiner .
Tonn et al., Biological Mass Spectrometry vol. 22, Issue 11, pp.
633-642 (1993). (Year: 1993). cited by examiner .
Haskins, Biomedical Mass Spectrometry, vol. 9 No. 7, pp. 269-277
(1982). (Year: 1982). cited by examiner .
Wolen, Journal of Clinical Pharmacology, 1986, vol. 26, pp.
419-424. (Year: 1986). cited by examiner .
Browne, Journal of Clinical Pharmacology, 1998; vol. 38, pp.
213-220. (Year: 1998). cited by examiner .
Baillie, Pharmacology Reviews, 1981, vol. 33, No. 2, pp. 81-132.
(Year: 1981). cited by examiner .
Gouyette, Biomedical and Environmental Mass Spectrometry, vol. 15,
pp. 243-247 (1988). (Year: 1988). cited by examiner .
Cherrah et al., Biomedical and Environmental Mass Spectrometry,
vol. 14, Issue 11, pp. 653-657 (1987). (Year: 1987). cited by
examiner .
Pieniaszek et al., Journal of Clinical Pharmacology, 1999, vol. 39,
pp. 817-825. (Year: 1999). cited by examiner .
Honma et al., Drug Metabolism and Disposition, vol. 15, No. 4, pp.
551-559 (1987). (Year: 1987). cited by examiner .
Akopian, A.N., L. Sivilotti, and J.N. Wood, A
tetrodotoxin-resistant voltage-gated sodium channel expressed by
sensory neurons. Nature, 1996. 379(6562): p. 257-62. cited by
applicant .
Black, J.A., et al., Multiple sodium channel isoforms and
mitogen-activated protein kinases are present in painful human
neuromas. Ann Neurol, 2008. 64(6): p. 644-53. cited by applicant
.
Blair, N.T. and B.P. Bean, Roles of tetrodotoxin (TTX)-sensitive
Na.sup.+current, TTX-resistant Na.sup.+current, and
Ca.sup.2+current in the action potentials of nociceptive sensory
neurons. J Neurosci., 2002. 22(23): p. 10277-90. cited by applicant
.
CAS Registry No. 1119379-37-1 (Mar. 12, 2009). cited by applicant
.
CAS Registry No. 1223014-19-4 (May 13, 2010). cited by applicant
.
CAS Registry No. 1241310-16-6 (Sep. 15, 2010). cited by applicant
.
CAS Registry No. 1252156-94-7 (Nov. 9, 2010). cited by applicant
.
CAS Registry No. 1258714-13-4 (Jan. 7, 2011). cited by applicant
.
CAS Registry No. 1258742-89-0 (Jan. 7, 2011). cited by applicant
.
CAS Registry No. 1281024-95-0 (Apr. 17, 2011). cited by applicant
.
CAS Registry No. 1281059-52-6 (Apr. 17, 2011). cited by applicant
.
CAS Registry No. 1281112-60-4 (Apr. 17, 2011). cited by applicant
.
CAS Registry No. 1287712-50-8 (Apr. 29, 2011). cited by applicant
.
CAS Registry No. 1301902-75-9 (May 29, 2011). cited by applicant
.
CAS Registry No. 1311734-41-4 (Jul. 7, 2011). cited by applicant
.
CAS Registry No. 1394673-41-6 (Sep. 18, 2012). cited by applicant
.
CAS Registry No. 1394698-15-7 (Sep. 18, 2012). cited by applicant
.
Catterall, W. A., Goldin, A. L., and Waxman, S. G., International
Union of Pharmacology. XLVII. Nomenclature and structure-function
relationships of voltage-gated sodium channels. Pharmacol Rev 57
(4), p. 397 (2005). cited by applicant .
Chahine, M., Chatelier, A., Babich, O., and Krupp, J. J.,
Voltage-gated sodium channels in neurological disorders. CNS Neurol
Disord Drug Targets 7 (2), p. 144-58 (2008). cited by applicant
.
Choi, J.S. and S.G. Waxman, Physiological interactions between
Na.sub.v1.7 and Na.sub.v1.8 sodium channels: a computer simulation
study. J Neurophysiol. 106(6): p. 3173-84; 2011. cited by applicant
.
Coward, K., et al., Immunolocalization of SNS/PN3 and NaN/SNS2
sodium channels in human pain states. Pain, 2000. 85(1-2): p.
41-50. cited by applicant .
Dieleman, J.P., et al., Incidence rates and treatment of
neuropathic pain conditions in the general population. Pain, 2008.
137(3): p. 681-8. cited by applicant .
Dong, X.W., et al., Small interfering RNA-mediated selective
knockdown of Na(.sub.v)1.8 tetrodotoxin-resistant sodium channel
reverses mechanical allodynia in neuropathic rats. Neuroscience,
2007. 146(2): p. 812-21. cited by applicant .
England, S., Voltage-gated sodium channels: the search for
subtype-selective analgesics. Expert Opin Investig Drugs 17 (12),
p. 1849-64 (2008). cited by applicant .
Gant, T.G., Using Deuterium in Drug Discovery: Leaving the Label in
the Drug, Journal of Medicinal Chemistry, vol. 57, No. 9, (May
2014), pp. 3599. cited by applicant .
Huang, H.L., et al., Proteomic profiling of neuromas reveals
alterations in protein composition and local protein synthesis in
hyper-excitable nerves. Mol Pain, 2008. 4: p. 33. cited by
applicant .
International Search Report and Written Opinion of the
International Searching Authority for International Application No.
PCT/US2014/069916 (dated Feb. 12, 2015). cited by applicant .
International Search Report and Written Opinion of the
International Searching Authority for International Application No.
PCT/US2014/013652 (dated Apr. 2, 2014). cited by applicant .
International Search Report and Written Opinion of the
International Searching Authority for International Application No.
PCT/US2018/032939 (dated Aug. 7, 2018). cited by applicant .
Jarvis, M.F., et al., A-803467, a potent and selective Na.sub.v1.8
sodium channel blocker, attenuates neuropathic and inflammatory
pain in the rat. Proc Natl Acad Sci. U S A, 2007. 104(20): p.
8520-5. cited by applicant .
Joshi, S.K., et al., Involvement of the TTX-resistant sodium
channel Nav1.8 in inflammatory and neuropathic, but not
post-operative, pain states. Pain, 2006. 123(1-2): pp. 75-82. cited
by applicant .
Krafte, D. S. and Bannon, A. W., Sodium channels and nociception:
recent concepts and therapeutic opportunities. Curr Opin Pharmacol
8 (1), p. 50-56 (2008). cited by applicant .
Lai, J., et al., Inhibition of neuropathic pain by decreased
expression of the tetrodotoxin-resistant sodium channel,
Na.sub.v1.8. Pain, 2002. 95(1-2): p. 143-52. cited by applicant
.
Qiu, F., et al., Increased expression of tetrodotoxin-resistant
sodium channels Na.sub.v1.8 and Na.sub.v1.9 within dorsal root
ganglia in a rat model of bone cancer pain. Neurosci. Lett. 512(2):
p. 61-6), 2012. cited by applicant .
Renganathan, M., T.R. Cummins, and S.G. Waxman, Contribution of
Na(.sub.v)1.8 sodium channels to action potential electrogenesis in
DRG neurons. J Neurophysiol., 2001. 86(2): p. 629-40. cited by
applicant .
Roza, C., et al., The tetrodotoxin-resistant Na.sup.+channel
Na.sub.v1.8 is essential for the expression of spontaneous activity
in damaged sensory axons of mice. J. Physiol., 2003. 550(Pt 3): p.
921-6. cited by applicant .
Ruangsri, S., et al., Relationship of axonal voltage-gated sodium
channel 1.8 (Na.sub.v1.8) mRNA accumulation to sciatic nerve
injury-induced painful neuropathy in rats. J Biol Chem. 286(46): p.
39836-47; 2011. cited by applicant .
Rush, A.M. and T.R. Cummins, Painful Research: Identification of a
Small-Molecule Inhibitor that Selectively Targets Na.sub.v1.8
Sodium Channels. Mol Interv, 2007. 7(4): p. 192-5). cited by
applicant .
Rush, A.M., et al., A single sodium channel mutation produces
hyper- or hypoexcitability in different types of neurons. Proc Natl
Acad Sci USA, 2006. 103(21): p. 8245-50. cited by applicant .
Soderpalm, B., Anticonvulsants: aspects of their mechanisms of
action. Eur J Pain 6 Suppl A, p. 3-9(2002). cited by applicant
.
Strickland, I.T., et al., Changes in the expression of NaV1.7,
Na.sub.v1.8 and Na.sub.v1.9 in a distinct population of dorsal root
ganglia innervating the rat knee joint in a model of chronic
inflammatory joint pain. Eur J Pain, 2008. 12(5): p. 564-72. cited
by applicant .
Sun, W., et al., Reduced conduction failure of the main axon of
polymodal nociceptive C-fibres contributes to painful diabetic
neuropathy in rats. Brain. 135(Pt 2): p. 359-75, 2012. cited by
applicant .
Wang, G. K., Mitchell, J., and Wang, S. Y., Block of persistent
late Na.sup.+currents by antidepressant sertraline and paroxetine.
J Membr Biol 222 (2), p. 79-90 (2008). cited by applicant .
Yiangou, Y., et al., SNS/PN3 and SNS2/NaN sodium channel-like
immunoreactivity in human adult and neonate injured sensory nerves.
FEBS Lett, 2000. 467(2-3): p. 249-52. cited by applicant .
Halford, Bethany, "Deuterium switcheroo breathes life into old
drugs," Drug Development, vol. 94, Iss. 27, pp. 1-13 (Jul. 4,
2016). cited by applicant.
|
Primary Examiner: Stockton; Laura L
Attorney, Agent or Firm: Barnes & Thornburg LLP
Parent Case Text
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Application
No. 62/507,172, filed May 16, 2017, and U.S. Provisional
Application No. 62/547,718, filed Aug. 18, 2017, both of which are
incorporated by reference in their entirety.
Claims
We claim:
1. A compound of formula I: ##STR00022## or a pharmaceutically
acceptable salt thereof, wherein R is H or
CH.sub.2OPO(OH).sub.2.
2. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein the compound of formula I is ##STR00023##
3. The compound of claim 1, wherein the compound of formula I is
##STR00024##
4. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein the compound of formula I is ##STR00025##
5. The compound of claim 1, wherein the compound of formula I is
##STR00026##
6. A pharmaceutical composition comprising a therapeutically
effective amount of the compound or pharmaceutically acceptable
salt of claim 1 and one or more pharmaceutically acceptable
carriers or vehicles.
7. A pharmaceutical composition comprising the compound or
pharmaceutically acceptable salt of claim 1 and one or more
pharmaceutically acceptable carriers or vehicles.
8. A method of inhibiting a voltage-gated sodium channel in a
subject comprising administering to the subject the compound or
pharmaceutically acceptable salt of claim 1.
9. The method of claim 8, wherein the voltage-gated sodium channel
is Nav1.8.
10. A method of treating or lessening the severity in a subject of
chronic pain, gut pain, neuropathic pain, musculoskeletal pain,
acute pain, inflammatory pain, cancer pain, idiopathic pain,
postsurgical pain, visceral pain, multiple sclerosis,
Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or
cardiac arrhythmia comprising administering to the subject an
effective amount of the compound or pharmaceutically acceptable
salt of claim 1.
11. The method of claim 10, where the method comprises treating or
lessening the severity in the subject of neuropathic pain.
12. The method of claim 11, wherein the neuropathic pain comprises
post-herpetic neuralgia, idiopathic small-fiber neuropathy, or
diabetic neuropathy.
13. The method of claim 10, wherein the method comprises treating
or lessening the severity in the subject of musculoskeletal
pain.
14. The method of claim 13, wherein the musculoskeletal pain
comprises osteoarthritis pain.
15. The method of claim 10, wherein the method comprises treating
or lessening the severity in the subject of acute pain.
16. The method of claim 15, wherein the acute pain comprises acute
post-operative pain.
17. The method of claim 10, wherein the method comprises treating
or lessening the severity in the subject of postsurgical pain.
18. The method of claim 17, wherein the postsurgical pain comprises
bunionectomy pain or abdominoplasty pain.
19. The method of claim 10, wherein the method comprises treating
or lessening the severity in the subject of visceral pain.
20. The method of claim 10, wherein said subject is treated with
one or more additional therapeutic agents administered concurrently
with, prior to, or subsequent to treatment with the compound,
pharmaceutically acceptable salt, or pharmaceutical composition.
Description
BACKGROUND
Pain is a protective mechanism that allows healthy animals to avoid
tissue damage and to prevent further damage to injured tissue.
Nonetheless there are many conditions where pain persists beyond
its usefulness, or where patients would benefit from inhibition of
pain. Neuropathic pain is a form of chronic pain caused by an
injury to the sensory nerves (Dieleman, J P, et al., Incidence
rates and treatment of neuropathic pain conditions in the general
population. Pain, 2008. 137(3): p. 681-8). Neuropathic pain can be
divided into two categories, pain caused by generalized metabolic
damage to the nerve and pain caused by a discrete nerve injury. The
metabolic neuropathies include post herpetic neuropathy, diabetic
neuropathy, and drug-induced neuropathy. Discrete nerve injuries
indications include post amputation pain, post-surgical nerve
injury pain, and nerve entrapment injuries like neuropathic back
pain.
Voltage-gated sodium channels (Na.sub.V's) are involved in pain
signaling Na.sub.V's are biological mediators of electrical
signaling as they mediate the rapid upstroke of the action
potential of many excitable cell types (e.g. neurons, skeletal
myocytes, cardiac myocytes). The evidence for the role of these
channels in normal physiology, the pathological states arising from
mutations in sodium channel genes, preclinical work in animal
models, and the clinical pharmacology of known sodium channel
modulating agents all point to the central role of Na.sub.V's in
pain sensation (Rush, A. M. and T. R. Cummins, Painful Research:
Identification of a Small-Molecule Inhibitor that Selectively
Targets Na.sub.V1.8 Sodium Channels. Mol Interv, 2007. 7(4): p.
192-5); England, S., Voltage-gated sodium channels: the search for
subtype-selective analgesics. Expert Opin Investig Drugs 17 (12),
p. 1849-64 (2008); Krafte, D. S. and Bannon, A. W., Sodium channels
and nociception: recent concepts and therapeutic opportunities.
Curr Opin Pharmacol 8 (1), p. 50-56 (2008)). Na.sub.V's mediate the
rapid upstroke of the action potential of many excitable cell types
(e.g. neurons, skeletal myocytes, cardiac myocytes), and thus are
involved in the initiation of signaling in those cells (Hille,
Bertil, Ion Channels of Excitable Membranes, Third ed. (Sinauer
Associates, Inc., Sunderland, Mass., 2001)). Because of the role
Na.sub.V's play in the initiation and propagation of neuronal
signals, antagonists that reduce Na.sub.V currents can prevent or
reduce neural signaling and Na.sub.V channels have been considered
likely targets to reduce pain in conditions where
hyper-excitability is observed (Chahine, M., Chatelier, A., Babich,
O., and Krupp, J. J., Voltage-gated sodium channels in neurological
disorders. CNS Neurol Disord Drug Targets 7 (2), p. 144-58 (2008)).
Several clinically useful analgesics have been identified as
inhibitors of Na.sub.V channels. The local anesthetic drugs such as
lidocaine block pain by inhibiting Na.sub.y channels, and other
compounds, such as carbamazepine, lamotrigine, and tricyclic
antidepressants that have proven effective at reducing pain have
also been suggested to act by sodium channel inhibition (Soderpalm,
B., Anticonvulsants: aspects of their mechanisms of action. Eur J
Pain 6 Suppl A, p. 3-9 (2002); Wang, G. K., Mitchell, J., and Wang,
S. Y., Block of persistent late Na.sup.+ currents by antidepressant
sertraline and paroxetine. J Membr Biol 222 (2), p. 79-90
(2008)).
The Na.sub.V's form a subfamily of the voltage-gated ion channel
super-family and comprises 9 isoforms, designated
Na.sub.V1.1-Na.sub.V1.9. The tissue localizations of the nine
isoforms vary. Na.sub.V1.4 is the primary sodium channel of
skeletal muscle, and Na.sub.V1.5 is primary sodium channel of
cardiac myocytes. Na.sub.V's 1.7, 1.8 and 1.9 are primarily
localized to the peripheral nervous system, while Na.sub.V's 1.1,
1.2, 1.3, and 1.6 are neuronal channels found in both the central
and peripheral nervous systems. The functional behaviors of the
nine isoforms are similar but distinct in the specifics of their
voltage-dependent and kinetic behavior (Catterall, W. A., Goldin,
A. L., and Waxman, S. G., International Union of Pharmacology.
XLVII. Nomenclature and structure-function relationships of
voltage-gated sodium channels. Pharmacol Rev 57 (4), p. 397
(2005)).
Upon their discovery, Na.sub.V1.8 channels were identified as
likely targets for analgesia (Akopian, A. N., L. Sivilotti, and J.
N. Wood, A tetrodotoxin-resistant voltage-gated sodium channel
expressed by sensory neurons. Nature, 1996. 379(6562): p. 257-62).
Since then, Na.sub.V1.8 has been shown to be a carrier of the
sodium current that maintains action potential firing in small DRG
neurons (Blair, N. T. and B. P. Bean, Roles of tetrodotoxin
(TTX)-sensitive Na+ current, TTX-resistant Na.sup.+ current, and
Ca.sup.2+ current in the action potentials of nociceptive sensory
neurons. J Neurosci., 2002. 22(23): p. 10277-90). Na.sub.V1.8 is
involved in spontaneous firing in damaged neurons, like those that
drive neuropathic pain (Roza, C., et al., The
tetrodotoxin-resistant Na channel Na.sub.V1.8 is essential for the
expression of spontaneous activity in damaged sensory axons of
mice. J. Physiol., 2003. 550(Pt 3): p. 921-6; Jarvis, M. F., et
al., A-803467, a potent and selective Na.sub.V1.8 sodium channel
blocker, attenuates neuropathic and inflammatory pain in the rat.
Proc Natl Acad Sci. USA, 2007. 104(20): p. 8520-5; Joshi, S. K., et
al., Involvement of the TTX-resistant sodium channel Nav1.8 in
inflammatory and neuropathic, but not post-operative, pain states.
Pain, 2006. 123(1-2): pp. 75-82; Lai, J., et al., Inhibition of
neuropathic pain by decreased expression of the
tetrodotoxin-resistant sodium channel, Na.sub.V1.8. Pain, 2002.
95(1-2): p. 143-52; Dong, X. W., et al., Small interfering
RNA-mediated selective knockdown of Na(.sub.V)1.8
tetrodotoxin-resistant sodium channel reverses mechanical allodynia
in neuropathic rats. Neuroscience, 2007. 146(2): p. 812-21; Huang,
H. L., et al., Proteomic profiling of neuromas reveals alterations
in protein composition and local protein synthesis in
hyper-excitable nerves. Mol Pain, 2008. 4: p. 33; Black, J. A., et
al., Multiple sodium channel isoforms and mitogen-activated protein
kinases are present in painful human neuromas. Ann Neurol, 2008.
64(6): p. 644-53; Coward, K., et al., Immunolocalization of SNS/PN3
and NaN/SNS2 sodium channels in human pain states. Pain, 2000.
85(1-2): p. 41-50; Yiangou, Y., et al., SNS/PN3 and SNS2/NaN sodium
channel-like immunoreactivity in human adult and neonate injured
sensory nerves. FEBS Lett, 2000. 467(2-3): p. 249-52; Ruangsri, S.,
et al., Relationship of axonal voltage-gated sodium channel 1.8
(Na.sub.V1.8) mRNA accumulation to sciatic nerve injury-induced
painful neuropathy in rats. J Biol Chem. 286(46): p. 39836-47). The
small DRG neurons where Na.sub.V1.8 is expressed include the
nociceptors involved in pain signaling Na.sub.V1.8 mediates large
amplitude action potentials in small neurons of the dorsal root
ganglia (Blair, N. T. and B. P. Bean, Roles of tetrodotoxin
(TTX)-sensitive Na.sup.+ current, TTX-resistant Na current, and
Ca.sup.2+ current in the action potentials of nociceptive sensory
neurons. J Neurosci., 2002. 22(23): p. 10277-90). Na.sub.V1.8 is
necessary for rapid repetitive action potentials in nociceptors,
and for spontaneous activity of damaged neurons. (Choi, J. S. and
S. G. Waxman, Physiological interactions between Na.sub.V1.7 and
Na.sub.V1.8 sodium channels: a computer simulation study. J
Neurophysiol. 106(6): p. 3173-84; Renganathan, M., T. R. Cummins,
and S. G. Waxman, Contribution of Na(.sub.V)1.8 sodium channels to
action potential electrogenesis in DRG neurons. J Neurophysiol.,
2001. 86(2): p. 629-40; Roza, C., et al., The
tetrodotoxin-resistant Na.sup.+ channel Na.sub.V1.8 is essential
for the expression of spontaneous activity in damaged sensory axons
of mice. J Physiol., 2003. 550(Pt 3): p. 921-6). In depolarized or
damaged DRG neurons, Na.sub.V1.8 appears to be a driver of
hyper-excitablility (Rush, A. M., et al., A single sodium channel
mutation produces hyper- or hypoexcitability in different types of
neurons. Proc Natl Acad Sci USA, 2006. 103(21): p. 8245-50). In
some animal pain models, Na.sub.V1.8 mRNA expression levels have
been shown to increase in the DRG (Sun, W., et al., Reduced
conduction failure of the main axon of polymodal nociceptive
C-fibers contributes to painful diabetic neuropathy in rats. Brain.
135(Pt 2): p. 359-75; Strickland, I. T., et al., Changes in the
expression of NaV1.7, Na.sub.V1.8 and Na.sub.V1.9 in a distinct
population of dorsal root ganglia innervating the rat knee joint in
a model of chronic inflammatory joint pain. Eur J Pain, 2008.
12(5): p. 564-72; Qiu, F., et al., Increased expression of
tetrodotoxin-resistant sodium channels Na.sub.V1.8 and Na.sub.V1.9
within dorsal root ganglia in a rat model of bone cancer pain.
Neurosci. Lett. 512(2): p. 61-6).
The primary drawback to some known Na.sub.V inhibitors is their
poor therapeutic window, and this is likely a consequence of their
lack of isoform selectivity. Since Na.sub.V1.8 is primarily
restricted to the neurons that sense pain, selective Na.sub.V1.8
blockers are unlikely to induce the adverse events common to
non-selective Na.sub.V blockers. Accordingly, there remains a need
to develop additional Na.sub.V channel modulators, preferably those
that are more potent and selective for Nav1.8, with increased
metabolic stability, increased solubility, and with fewer side
effects.
A class of pyridone amide compounds useful as inhibitors of
Na.sub.v1.8 sodium channels was described in International
Publication No. WO 2014/120808 A9 and US Publication No.
2014/0213616 A1, and prodrugs of these compounds were described in
International Publication No. WO 2015/089361 A1 and US Publication
No. 2015/0166589 A1, all of which are incorporated by reference in
their entirety. Those pyridone amide compounds address some of the
drawbacks of prior Na.sub.v18 inhibitors, but further improvements
may still be made.
SUMMARY
In one aspect, the invention relates to a compound of formula
I:
##STR00002## or a pharmaceutically acceptable salt thereof, wherein
R is H or CH.sub.2OPO(OH).sub.2.
In another aspect, the invention relates to a compound of formula I
that is
##STR00003## or a pharmaceutically acceptable salt thereof.
In another aspect, the invention relates to a compound of formula I
that is
##STR00004##
In another aspect, the invention relates to a compound of formula I
that is
##STR00005## or a pharmaceutically acceptable salt thereof.
In another aspect, the invention relates to a compound of formula I
that is
##STR00006##
In another aspect, the invention relates to a pharmaceutical
composition comprising the compound of formula I, or a
pharmaceutically acceptable salt thereof, and one or more
pharmaceutically acceptable carriers or vehicles.
In still another aspect, the invention relates to a method of
inhibiting a voltage gated sodium channel in a subject by
administering the compound of formula I, pharmaceutically
acceptable salt, or pharmaceutical composition to the subject.
In yet another aspect, the invention relates to a method of
treating or lessening the severity in a subject of a variety of
diseases, disorders, or conditions, including, but not limited to,
chronic pain, gut pain, neuropathic pain, musculoskeletal pain,
acute pain, inflammatory pain, cancer pain, idiopathic pain,
postsurgical pain (e.g., bunionectomy pain or abdominoplasty pain),
visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome,
incontinence, pathological cough, and cardiac arrhythmia, by
administering the compound of formula I, pharmaceutically
acceptable salt, or pharmaceutical composition to the subject.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a plot of the percentage of Compounds 7 and 10 remaining
over time during incubation in the presence of rat liver
microsomes.
FIG. 2 is a plot of the percentage of Compounds 7 and 10 remaining
over time during incubation in the presence of dog liver
microsomes.
FIG. 3 is a plot of the percentage of Compounds 7 and 10 remaining
over time during incubation in the presence of monkey liver
microsomes.
FIG. 4 is a plot of the percentage of Compounds 7 and 10 remaining
over time during incubation in the presence of human liver
microsomes.
FIG. 5 is a plot of the plasma concentration of Compounds 7 and 10
over time after intravenous administration to Male Sprague Dawley
rats.
DETAILED DESCRIPTION
In one aspect, the invention relates to a compound of formula
I:
##STR00007## or a pharmaceutically acceptable salt thereof, wherein
R is H or CH.sub.2OPO(OH).sub.2.
In another aspect, the invention relates to a compound of formula I
that is
##STR00008## or a pharmaceutically acceptable salt thereof.
In another aspect, the invention relates to a compound of formula I
that is
##STR00009##
In another aspect, the invention relates to a compound of formula I
that is
##STR00010## or a pharmaceutically acceptable salt thereof.
In another aspect, the invention relates to a compound of formula I
that is
##STR00011##
The compound of formula I in which R is CH.sub.2OPO(OH).sub.2, and
pharmaceutically acceptable salts thereof, are prodrugs of the
parent compound in which R is H.
As used herein, the term "prodrug" refers to compounds and salts
which are drug precursors which, following administration and
absorption, release the drug in vivo via some metabolic process. In
general, a prodrug possesses less biological activity than its
parent drug. A prodrug may also improve the physical properties of
the parent drug and/or it may improve overall drug efficacy, for
example through the reduction of toxicity and unwanted effects of a
drug by controlling its absorption, blood levels, metabolic
distribution and cellular uptake.
As used herein, the term "parent compound" or "parent drug" refers
to the biologically active entity that is released via enzymatic
action of a metabolic or a catabolic process, or via a chemical
process following administration of the prodrug. The parent
compound may also be the starting material for the preparation of
its corresponding prodrug.
For purposes of this invention, the chemical elements are
identified in accordance with the Periodic Table of the Elements,
CAS version, Handbook of Chemistry and Physics, 75.sup.th Ed.
Additionally, general principles of organic chemistry are described
in "Organic Chemistry," Thomas Sorrell, University Science Books,
Sausalito: 1999, and "March's Advanced Organic Chemistry," 5.sup.th
Ed., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New
York: 2001, the entire contents of which are hereby incorporated by
reference.
As used herein, the term "compounds of the invention" refers to the
compounds of formula I, and all of the embodiments thereof, as
described herein.
As used herein, the term "compound," when referring to the
compounds of the invention, refers to a collection of molecules
having identical chemical structures, except that there may be
isotopic variation amongst the constituent atoms of the molecules.
The term "compound" includes such a collection of molecules without
regard to the purity of a given sample containing the collection of
molecules. Thus, the term "compound" includes such a collection of
molecules in pure form or in a mixture (e.g., solution, suspension,
or colloid) with one or more other substances.
In the specification and claims, unless otherwise specified, any
atom not specifically designated as a particular isotope in any
compound of the invention is meant to represent any stable isotope
of the specified element. In the Examples, where an atom is not
specifically designated as a particular isotope in any compound of
the invention, no effort was made to enrich that atom in a
particular isotope, and therefore a person of ordinary skill in the
art would understand that such atom likely was present at
approximately the natural abundance isotopic composition of the
specified element.
As used herein, the term "stable," when referring to an isotope,
means that the isotope is not known to undergo spontaneous
radioactive decay. Stable isotopes include, but are not limited to,
the isotopes for which no decay mode is identified in V. S. Shirley
& C. M. Lederer, Isotopes Project, Nuclear Science Division,
Lawrence Berkeley Laboratory, Table of Nuclides (January 1980).
As used herein in the specification and claims, "H" refers to
hydrogen and includes any stable isotope of hydrogen. In the
Examples, where an atom is designated as "H," no effort was made to
enrich that atom in a particular isotope of hydrogen, and therefore
a person of ordinary skill in the art would understand that such
hydrogen atom likely was present at approximately the natural
abundance isotopic composition of hydrogen.
As used herein, "D" and "d" both refer to deuterium (.sup.2H).
In some embodiments, the compounds of the invention, and
pharmaceutically acceptable salts thereof, include one or more
atoms having an atomic mass or mass number which differs from the
atomic mass or mass number of the most abundant isotope of the
specified element ("isotope-labelled" compounds and salts).
Examples of stable isotopes which are commercially available and
suitable for the invention include without limitation isotopes of
hydrogen, carbon, nitrogen, oxygen, and phosphorus, for example
.sup.2H, .sup.13C, .sup.15N, .sup.18O, .sup.17O, and .sup.31P,
respectively.
The isotope-labelled compounds and salts can be used in a number of
beneficial ways, including as medicaments. In some embodiments, the
isotope-labelled compounds and salts are deuterium
(.sup.2H)-labelled. Deuterium (.sup.2H)-labelled compounds and
salts are therapeutically useful with potential therapeutic
advantages over the non-.sup.2H-labelled compounds. In general,
deuterium (.sup.2H)-labelled compounds and salts can have higher
metabolic stability as compared to those that are not
isotope-labelled owing to the kinetic isotope effect described
below. Higher metabolic stability translates directly into an
increased in vivo half-life or lower dosages, which under most
circumstances would represent a preferred embodiment of the present
invention. The isotope-labelled compounds and salts can usually be
prepared by carrying out the procedures disclosed in the synthesis
schemes, the examples and the related description, replacing a
non-isotope-labelled reactant by a readily available
isotope-labelled reactant.
The deuterium (.sup.2H)-labelled compounds and salts can manipulate
the rate of oxidative metabolism of the compound by way of the
primary kinetic isotope effect. The primary kinetic isotope effect
is a change of the rate for a chemical reaction that results from
exchange of isotopic nuclei, which in turn is caused by the change
in ground state energies of the covalent bonds involved in the
reaction. Exchange of a heavier isotope usually results in a
lowering of the ground state energy for a chemical bond and thus
causes a reduction in the rate-limiting bond breakage. If the bond
breakage occurs in or in the vicinity of a saddle-point region
along the coordinate of a multi-product reaction, the product
distribution ratios can be altered substantially. For explanation:
if deuterium is bonded to a carbon atom at a non-exchangeable
position, rate differences of k.sub.H/k.sub.D=2-7 are typical. For
a further discussion, see S. L. Harbeson and R. D. Tung, Deuterium
In Drug Discovery and Development, Ann. Rep. Med. Chem. 2011, 46,
403-417, incorporated in its entirety herein by reference.
The concentration of an isotope (e.g., deuterium) incorporated at a
given position of an isotope-labelled compound of the invention, or
a pharmaceutically acceptable salt thereof, may be defined by the
isotopic enrichment factor. The term "isotopic enrichment factor,"
as used herein, means the ratio between the abundance of an isotope
at a given position in an isotope-labeled compound (or salt) and
the natural abundance of the isotope.
Where an atom in a compound of the invention, or a pharmaceutically
acceptable salt thereof, is designated as deuterium, such compound
(or salt) has an isotopic enrichment factor for such atom of at
least 3000 (45% deuterium incorporation). In some embodiments, the
isotopic enrichment factor is at least 3500 (52.5% deuterium
incorporation), at least 4000 (60% deuterium incorporation), at
least 4500 (67.5% deuterium incorporation), at least 5000 (75%
deuterium incorporation), at least 5500 (82.5% deuterium
incorporation), at least 6000 (90% deuterium incorporation), at
least 6333 (95% deuterium incorporation), at least 6466.7 (97%
deuterium incorporation), at least 6600 (99% deuterium
incorporation), or at least 6633.3 (99.5% deuterium
incorporation).
In some embodiments, the positions not designated specifically as
"D," "d," or "deuterium" in the compounds of the invention shall be
understood to have hydrogen at its natural abundance isotopic
composition.
Salts, Compositions, Uses, Formulation, Administration and
Additional Agents
Pharmaceutically Acceptable Salts and Compositions
As discussed herein, the invention provides compounds, and
pharmaceutically acceptable salts thereof, that are inhibitors of
voltage-gated sodium channels, and thus the present compounds, and
pharmaceutically acceptable salts thereof, are useful for the
treatment of diseases, disorders, and conditions including, but not
limited to chronic pain, gut pain, neuropathic pain,
musculoskeletal pain, acute pain, inflammatory pain, cancer pain,
idiopathic pain, postsurgical pain (e.g., bunionectomy pain or
abdominoplasty pain), visceral pain, multiple sclerosis,
Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or
cardiac arrhythmia. Accordingly, in another aspect of the
invention, pharmaceutical compositions are provided, wherein these
compositions comprise a compound as described herein, or a
pharmaceutically acceptable salt thereof, and optionally comprise a
pharmaceutically acceptable carrier, adjuvant or vehicle. In
certain embodiments, these compositions optionally further comprise
one or more additional therapeutic agents. In some embodiments, the
additional therapeutic agent is a sodium channel inhibitor.
As used herein, the term "pharmaceutically acceptable salt" refers
to those salts which are, within the scope of sound medical
judgement, suitable for use in contact with the tissues of humans
and lower animals without undue toxicity, irritation, allergic
response and the like, and are commensurate with a reasonable
benefit/risk ratio. A "pharmaceutically acceptable salt" of a
compound of this invention includes any non-toxic salt that, upon
administration to a recipient, is capable of providing, either
directly or indirectly, a compound of this invention or an
inhibitorily active metabolite or residue thereof. As used herein,
the term "inhibitorily active metabolite or residue thereof" means
that a metabolite or residue thereof is also an inhibitor of a
voltage-gated sodium channel.
Pharmaceutically acceptable salts are well known in the art. For
example, S. M. Berge, et al. describe pharmaceutically acceptable
salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19,
incorporated herein by reference. Pharmaceutically acceptable salts
of the compound of this invention include those derived from
suitable inorganic and organic acids and bases. Examples of
pharmaceutically acceptable, nontoxic acid addition salts are salts
of an amino group formed with inorganic acids such as hydrochloric
acid, hydrobromic acid, phosphoric acid, sulfuric acid and
perchloric acid or with organic acids such as acetic acid, oxalic
acid, maleic acid, tartaric acid, citric acid, succinic acid or
malonic acid or by using other methods used in the art such as ion
exchange. Other pharmaceutically acceptable salts include adipate,
alginate, ascorbate, aspartate, benzenesulfonate, benzoate,
bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate,
cyclopentanepropionate, digluconate, dodecylsulfate,
ethanesulfonate, formate, fumarate, glucoheptonate,
glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate,
hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate,
laurate, lauryl sulfate, malate, maleate, malonate,
methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,
oleate, oxalate, palmitate, pamoate, pectinate, persulfate,
3-phenylpropionate, phosphate, picrate, pivalate, propionate,
stearate, succinate, sulfate, tartrate, thiocyanate,
p-toluenesulfonate, undecanoate, valerate salts, and the like.
Salts derived from appropriate bases include alkali metal, alkaline
earth metal, ammonium and N.sup.+(C.sub.1-4alkyl).sub.4 salts.
Representative alkali or alkaline earth metal salts include sodium,
lithium, potassium, calcium, magnesium, and the like. Further
pharmaceutically acceptable salts include, when appropriate,
nontoxic ammonium, quaternary ammonium, and amine cations formed
using counterions such as halide, hydroxide, carboxylate, sulfate,
phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate.
In some embodiments, a pharmaceutically acceptable salt of
##STR00012## has the formula:
##STR00013## wherein X is --PO(OH)O.sup.-M.sup.+,
--PO(O.sup.-).sub.2.2M.sup.+, or --PO(O.sup.-).sub.2.D.sup.2+;
M.sup.+ is a pharmaceutically acceptable monovalent cation; and
D.sup.2+ is a pharmaceutically acceptable divalent cation.
As used herein, the term "monovalent cation" (M.sup.+) refers to a
cation bearing a single unit of positive charge. Monovalent cations
include ammonium (e.g., N(R.sup.9).sub.4, wherein R.sup.9 is H or
C.sub.1-C.sub.4 alkyl), alkali metal ions such as sodium, lithium
and potassium ions, dicyclohexylamine ion, and N-methyl-D-glucamine
ion. It is recognized that if the definition 2M.sup.+ is present,
each of M.sup.+ may be the same or different.
As used herein, the term "divalent cation" (D.sup.2+) refers to a
cation bearing two units of positive charge. Divalent cations
include alkaline earth metal ions such as calcium and magnesium
ions, as well as divalent aluminum ions.
The terms "monovalent cation" and "divalent cation" include amino
acid cations such as monovalent or divalent ions of arginine,
lysine, ornithine, and so forth. The basic nitrogen-containing
groups may be protonated or may be quaternized with such agents as:
lower alkyl halides, such as methyl, ethyl, propyl, and butyl
chloride, bromides and iodides; dialkyl sulfates like dimethyl,
diethyl, dibutyl; diamyl sulfates; long chain halides such as
decyl, lauryl, myristyl and stearyl chlorides, bromides and
iodides; aralkyl halides like benzyl bromide and others.
As described herein, the pharmaceutically acceptable compositions
of the invention additionally comprise a pharmaceutically
acceptable carrier, adjuvant, or vehicle, which, as used herein,
includes any and all solvents, diluents, or other liquid vehicle,
dispersion or suspension aids, surface active agents, isotonic
agents, thickening or emulsifying agents, preservatives, solid
binders, lubricants and the like, as suited to the particular
dosage form desired. Remington's Pharmaceutical Sciences, Sixteenth
Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980)
discloses various carriers used in formulating pharmaceutically
acceptable compositions and known techniques for the preparation
thereof. Except insofar as any conventional carrier medium is
incompatible with the compounds of the invention, such as by
producing any undesirable biological effect or otherwise
interacting in a deleterious manner with any other component(s) of
the pharmaceutically acceptable composition, its use is
contemplated to be within the scope of this invention. Some
examples of materials which can serve as pharmaceutically
acceptable carriers include, but are not limited to, ion
exchangers, alumina, aluminum stearate, lecithin, serum proteins,
such as human serum albumin, buffer substances such as phosphates,
glycine, sorbic acid, or potassium sorbate, partial glyceride
mixtures of saturated vegetable fatty acids, water, salts or
electrolytes, such as protamine sulfate, disodium hydrogen
phosphate, potassium hydrogen phosphate, sodium chloride, zinc
salts, colloidal silica, magnesium trisilicate, polyvinyl
pyrrolidone, polyacrylates, waxes,
polyethylene-polyoxypropylene-block polymers, wool fat, sugars such
as lactose, glucose and sucrose; starches such as corn starch and
potato starch; cellulose and its derivatives such as sodium
carboxymethyl cellulose, ethyl cellulose and cellulose acetate;
powdered tragacanth; malt; gelatin; talc; excipients such as cocoa
butter and suppository waxes; oils such as peanut oil, cottonseed
oil; safflower oil; sesame oil; olive oil; corn oil and soybean
oil; glycols; such a propylene glycol or polyethylene glycol;
esters such as ethyl oleate and ethyl laurate; agar; buffering
agents such as magnesium hydroxide and aluminum hydroxide; alginic
acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl
alcohol, and phosphate buffer solutions, as well as other non-toxic
compatible lubricants such as sodium lauryl sulfate and magnesium
stearate, as well as coloring agents, releasing agents, coating
agents, sweetening, flavoring and perfuming agents, preservatives
and antioxidants can also be present in the composition, according
to the judgment of the formulator.
In another aspect, the invention features a pharmaceutical
composition comprising a compound of the invention, or a
pharmaceutically acceptable salt thereof, and a pharmaceutically
acceptable carrier.
In another aspect, the invention features a pharmaceutical
composition comprising a therapeutically effective amount of a
compound, or a pharmaceutically acceptable salt thereof, and one or
more pharmaceutically acceptable carriers or vehicles.
Uses of Compounds and Pharmaceutically Acceptable Salts and
Compositions
In another aspect, the invention features a method of inhibiting a
voltage-gated sodium channel in a subject comprising administering
to the subject a compound of the invention or a pharmaceutically
acceptable salt thereof or a pharmaceutical composition thereof. In
another aspect, the voltage-gated sodium channel is Nav1.8.
In yet another aspect, the invention features a method of treating
or lessening the severity in a subject of chronic pain, gut pain,
neuropathic pain, musculoskeletal pain, acute pain, inflammatory
pain, cancer pain, idiopathic pain, postsurgical pain (e.g.,
bunionectomy pain or abdominoplasty pain), visceral pain, multiple
sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological
cough, or cardiac arrhythmia comprising administering an effective
amount of a compound of the invention, a pharmaceutically
acceptable salt thereof or a pharmaceutical composition
thereof.
In yet another aspect, the invention features a method of treating
or lessening the severity in a subject of chronic pain, gut pain,
neuropathic pain, musculoskeletal pain, acute pain, inflammatory
pain, cancer pain, idiopathic pain, postsurgical pain, bunionectomy
pain, multiple sclerosis, Charcot-Marie-Tooth syndrome,
incontinence, or cardiac arrhythmia comprising administering an
effective amount of a compound of the invention, a pharmaceutically
acceptable salt thereof or a pharmaceutical composition
thereof.
In yet another aspect, the invention features a method of treating
or lessening the severity in a subject of gut pain, wherein gut
pain comprises inflammatory bowel disease pain, Crohn's disease
pain or interstitial cystitis pain wherein said method comprises
administering an effective amount of a compound of the invention, a
pharmaceutically acceptable salt thereof or a pharmaceutical
composition thereof.
In yet another aspect, the invention features a method of treating
or lessening the severity in a subject of neuropathic pain
comprising administering an effective amount of a compound of the
invention, a pharmaceutically acceptable salt thereof or a
pharmaceutical composition thereof. In some aspects, the
neuropathic pain comprises post-herpetic neuralgia or idiopathic
small-fiber neuropathy. As used herein, the phrase "idiopathic
small-fiber neuropathy" shall be understood to include any small
fiber neuropathy.
In yet another aspect, the invention features a method of treating
or lessening the severity in a subject of neuropathic pain, wherein
neuropathic pain comprises post-herpetic neuralgia, diabetic
neuralgia, painful HIV-associated sensory neuropathy, trigeminal
neuralgia, burning mouth syndrome, post-amputation pain, phantom
pain, painful neuroma; traumatic neuroma; Morton's neuroma; nerve
entrapment injury, spinal stenosis, carpal tunnel syndrome,
radicular pain, sciatica pain; nerve avulsion injury, brachial
plexus avulsion injury; complex regional pain syndrome, drug
therapy induced neuralgia, cancer chemotherapy induced neuralgia,
anti-retroviral therapy induced neuralgia; post spinal cord injury
pain, idiopathic small-fiber neuropathy, idiopathic sensory
neuropathy or trigeminal autonomic cephalalgia wherein said method
comprises administering an effective amount of a compound of the
invention, a pharmaceutically acceptable salt thereof or a
pharmaceutical composition thereof.
In yet another aspect, the invention features a method of treating
or lessening the severity in a subject of musculoskeletal pain
comprising administering an effective amount of a compound of the
invention, a pharmaceutically acceptable salt thereof or a
pharmaceutical composition thereof. In some aspects, the
musculoskeletal pain comprises osteoarthritis pain.
In yet another aspect, the invention features a method of treating
or lessening the severity in a subject of musculoskeletal pain,
wherein musculoskeletal pain comprises osteoarthritis pain, back
pain, cold pain, burn pain or dental pain wherein said method
comprises administering an effective amount of a compound of the
invention, a pharmaceutically acceptable salt thereof or a
pharmaceutical composition thereof.
In yet another aspect, the invention features a method of treating
or lessening the severity in a subject of inflammatory pain,
wherein inflammatory pain comprises rheumatoid arthritis pain or
vulvodynia wherein said method comprises administering an effective
amount of a compound of the invention, a pharmaceutically
acceptable salt thereof or a pharmaceutical composition
thereof.
In yet another aspect, the invention features a method of treating
or lessening the severity in a subject of inflammatory pain,
wherein inflammatory pain comprises rheumatoid arthritis pain
wherein said method comprises administering an effective amount of
a compound of the invention, a pharmaceutically acceptable salt
thereof or a pharmaceutical composition thereof.
In yet another aspect, the invention features a method of treating
or lessening the severity in a subject of idiopathic pain, wherein
idiopathic pain comprises fibromyalgia pain wherein said method
comprises administering an effective amount of a compound of the
invention, a pharmaceutically acceptable salt thereof or a
pharmaceutical composition thereof.
In yet another aspect, the invention features a method of treating
or lessening the severity in a subject of pathological cough
wherein said method comprises administering an effective amount of
a compound of the invention, a pharmaceutically acceptable salt
thereof or a pharmaceutical composition thereof.
In yet another aspect, the invention features a method of treating
or lessening the severity in a subject of acute pain comprising
administering an effective amount of a compound of the invention, a
pharmaceutically acceptable salt thereof or a pharmaceutical
composition thereof. In some aspects, the acute pain comprises
acute post-operative pain.
In yet another aspect, the invention features a method of treating
or lessening the severity in a subject of postsurgical pain (e.g.,
bunionectomy pain or abdominoplasty pain) comprising administering
an effective amount of a compound of the invention, a
pharmaceutically acceptable salt thereof or a pharmaceutical
composition thereof.
In yet another aspect, the invention features a method of treating
or lessening the severity in a subject of bunionectomy pain
comprising administering an effective amount of a compound of the
invention, a pharmaceutically acceptable salt thereof or a
pharmaceutical composition thereof.
In yet another aspect, the invention features a method of treating
or lessening the severity in a subject of abdominoplasty pain
comprising administering an effective amount of a compound of the
invention, a pharmaceutically acceptable salt thereof or a
pharmaceutical composition thereof.
In yet another aspect, the invention features a method of treating
or lessening the severity in a subject of visceral pain comprising
administering an effective amount of a compound of the invention, a
pharmaceutically acceptable salt thereof or a pharmaceutical
composition thereof. In some aspects, the visceral pain comprises
visceral pain from abdominoplasty.
In yet another aspect, the invention features a method wherein the
subject is treated with one or more additional therapeutic agents
administered concurrently with, prior to, or subsequent to
treatment with an effective amount of the compound,
pharmaceutically acceptable salt or pharmaceutical composition. In
some embodiments, the additional therapeutic agent is a sodium
channel inhibitor.
In another aspect, the invention features a method of inhibiting a
voltage-gated sodium channel in a biological sample comprising
contacting the biological sample with an effective amount of a
compound of the invention, a pharmaceutically acceptable salt
thereof or a pharmaceutical composition thereof. In another aspect,
the voltage-gated sodium channel is Nav1.8.
In another aspect, the invention features a method of treating or
lessening the severity in a subject of acute pain, chronic pain,
neuropathic pain, inflammatory pain, arthritis, migraine, cluster
headaches, trigeminal neuralgia, herpetic neuralgia, general
neuralgias, epilepsy, epilepsy conditions, neurodegenerative
disorders, psychiatric disorders, anxiety, depression, bipolar
disorder, myotonia, arrhythmia, movement disorders, neuroendocrine
disorders, ataxia, multiple sclerosis, irritable bowel syndrome,
incontinence, pathological cough, visceral pain, osteoarthritis
pain, postherpetic neuralgia, diabetic neuropathy, radicular pain,
sciatica, back pain, head pain, neck pain, severe pain, intractable
pain, nociceptive pain, breakthrough pain, postsurgical pain (e.g.,
bunionectomy pain or abdominoplasty pain), cancer pain, stroke,
cerebral ischemia, traumatic brain injury, amyotrophic lateral
sclerosis, stress induced angina, exercise induced angina,
palpitations, hypertension, or abnormal gastro-intestinal motility,
comprising administering an effective amount of a compound of the
invention, a pharmaceutically acceptable salt thereof or a
pharmaceutical composition thereof.
In another aspect, the invention features a method of treating or
lessening the severity in a subject of femur cancer pain;
non-malignant chronic bone pain; rheumatoid arthritis;
osteoarthritis; spinal stenosis; neuropathic low back pain;
myofascial pain syndrome; fibromyalgia; temporomandibular joint
pain; chronic visceral pain, abdominal pain; pancreatic pain; IBS
pain; chronic and acute headache pain; migraine; tension headache;
cluster headaches; chronic and acute neuropathic pain,
post-herpetic neuralgia; diabetic neuropathy; HIV-associated
neuropathy; trigeminal neuralgia; Charcot-Marie-Tooth neuropathy;
hereditary sensory neuropathy; peripheral nerve injury; painful
neuromas; ectopic proximal and distal discharges; radiculopathy;
chemotherapy induced neuropathic pain; radiotherapy-induced
neuropathic pain; post-mastectomy pain; central pain; spinal cord
injury pain; post-stroke pain; thalamic pain; complex regional pain
syndrome; phantom pain; intractable pain; acute pain, acute
post-operative pain; acute musculoskeletal pain; joint pain;
mechanical low back pain; neck pain; tendonitis; injury pain;
exercise pain; acute visceral pain; pyelonephritis; appendicitis;
cholecystitis; intestinal obstruction; hernias; chest pain, cardiac
pain; pelvic pain, renal colic pain, acute obstetric pain, labor
pain; cesarean section pain; acute inflammatory pain, burn pain,
trauma pain; acute intermittent pain, endometriosis; acute herpes
zoster pain; sickle cell anemia; acute pancreatitis; breakthrough
pain; orofacial pain; sinusitis pain; dental pain; multiple
sclerosis (MS) pain; pain in depression; leprosy pain; Behcet's
disease pain; adiposis dolorosa; phlebitic pain; Guillain-Barre
pain; painful legs and moving toes; Haglund syndrome;
erythromelalgia pain; Fabry's disease pain; bladder and urogenital
disease; urinary incontinence, pathological cough; hyperactive
bladder; painful bladder syndrome; interstitial cystitis (IC);
prostatitis; complex regional pain syndrome (CRPS), type I, complex
regional pain syndrome (CRPS) type II; widespread pain, paroxysmal
extreme pain, pruritus, tinnitus, or angina-induced pain,
comprising administering an effective amount of a compound of the
invention, a pharmaceutically acceptable salt thereof or a
pharmaceutical composition thereof.
Compounds, Pharmaceutically Acceptable Salts, and Compositions for
Use
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use as a medicament.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of inhibiting a
voltage-gated sodium channel in a subject. In another aspect, the
voltage-gated sodium channel is Nav1.8.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of treating or lessening
the severity in a subject of chronic pain, gut pain, neuropathic
pain, musculoskeletal pain, acute pain, inflammatory pain, cancer
pain, idiopathic pain, postsurgical pain (e.g., bunionectomy pain
or abdominoplasty pain), visceral pain, multiple sclerosis,
Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or
cardiac arrhythmia.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of treating or lessening
the severity in a subject of chronic pain, gut pain, neuropathic
pain, musculoskeletal pain, acute pain, inflammatory pain, cancer
pain, idiopathic pain, postsurgical pain, bunionectomy pain,
multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, or
cardiac arrhythmia.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of treating or lessening
the severity in a subject of gut pain, wherein gut pain comprises
inflammatory bowel disease pain, Crohn's disease pain or
interstitial cystitis pain.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of treating or lessening
the severity in a subject of neuropathic pain. In some aspects, the
neuropathic pain comprises post-herpetic neuralgia or idiopathic
small-fiber neuropathy. As used herein, the phrase "idiopathic
small-fiber neuropathy" shall be understood to include any small
fiber neuropathy.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of treating or lessening
the severity in a subject of neuropathic pain, wherein neuropathic
pain comprises post-herpetic neuralgia, diabetic neuralgia, painful
HIV-associated sensory neuropathy, trigeminal neuralgia, burning
mouth syndrome, post-amputation pain, phantom pain, painful
neuroma; traumatic neuroma; Morton's neuroma; nerve entrapment
injury, spinal stenosis, carpal tunnel syndrome, radicular pain,
sciatica pain; nerve avulsion injury, brachial plexus avulsion
injury; complex regional pain syndrome, drug therapy induced
neuralgia, cancer chemotherapy induced neuralgia, anti-retroviral
therapy induced neuralgia; post spinal cord injury pain, idiopathic
small-fiber neuropathy, idiopathic sensory neuropathy or trigeminal
autonomic cephalalgia.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of treating or lessening
the severity in a subject of musculoskeletal pain. In some aspects,
the musculoskeletal pain comprises osteoarthritis pain.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of treating or lessening
the severity in a subject of musculoskeletal pain, wherein
musculoskeletal pain comprises osteoarthritis pain, back pain, cold
pain, burn pain or dental pain.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of treating or lessening
the severity in a subject of inflammatory pain, wherein
inflammatory pain comprises rheumatoid arthritis pain or
vulvodynia.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of treating or lessening
the severity in a subject of inflammatory pain, wherein
inflammatory pain comprises rheumatoid arthritis pain.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of treating or lessening
the severity in a subject of idiopathic pain, wherein idiopathic
pain comprises fibromyalgia pain.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of treating or lessening
the severity in a subject of pathological cough.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of treating or lessening
the severity in a subject of acute pain. In some aspects, the acute
pain comprises acute post-operative pain.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of treating or lessening
the severity in a subject of postsurgical pain (e.g., bunionectomy
pain or abdominoplasty pain).
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of treating or lessening
the severity in a subject of bunionectomy pain.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of treating or lessening
the severity in a subject of abdominoplasty pain.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of treating or lessening
the severity in a subject of visceral pain. In some aspects, the
visceral pain comprises visceral pain from abdominoplasty.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method wherein the subject is
treated with one or more additional therapeutic agents administered
concurrently with, prior to, or subsequent to treatment with an
effective amount of the compound, pharmaceutically acceptable salt
or pharmaceutical composition. In some embodiments, the additional
therapeutic agent is a sodium channel inhibitor.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of inhibiting a
voltage-gated sodium channel in a biological sample comprising
contacting the biological sample with an effective amount of a
compound of the invention, a pharmaceutically acceptable salt
thereof or a pharmaceutical composition thereof. In another aspect,
the voltage-gated sodium channel is Nav1.8.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of treating or lessening
the severity in a subject of acute pain, chronic pain, neuropathic
pain, inflammatory pain, arthritis, migraine, cluster headaches,
trigeminal neuralgia, herpetic neuralgia, general neuralgias,
epilepsy, epilepsy conditions, neurodegenerative disorders,
psychiatric disorders, anxiety, depression, bipolar disorder,
myotonia, arrhythmia, movement disorders, neuroendocrine disorders,
ataxia, multiple sclerosis, irritable bowel syndrome, incontinence,
pathological cough, visceral pain, osteoarthritis pain,
postherpetic neuralgia, diabetic neuropathy, radicular pain,
sciatica, back pain, head pain, neck pain, severe pain, intractable
pain, nociceptive pain, breakthrough pain, postsurgical pain (e.g.,
bunionectomy pain or abdominoplasty pain), cancer pain, stroke,
cerebral ischemia, traumatic brain injury, amyotrophic lateral
sclerosis, stress induced angina, exercise induced angina,
palpitations, hypertension, or abnormal gastro-intestinal
motility.
In another aspect, the invention features a compound of the
invention, or a pharmaceutically acceptable salt or pharmaceutical
composition thereof, for use in a method of treating or lessening
the severity in a subject of femur cancer pain; non-malignant
chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal
stenosis; neuropathic low back pain; myofascial pain syndrome;
fibromyalgia; temporomandibular joint pain; chronic visceral pain,
abdominal pain; pancreatic pain; IBS pain; chronic and acute
headache pain; migraine; tension headache; cluster headaches;
chronic and acute neuropathic pain, post-herpetic neuralgia;
diabetic neuropathy; HIV-associated neuropathy; trigeminal
neuralgia; Charcot-Marie-Tooth neuropathy; hereditary sensory
neuropathy; peripheral nerve injury; painful neuromas; ectopic
proximal and distal discharges; radiculopathy; chemotherapy induced
neuropathic pain; radiotherapy-induced neuropathic pain;
post-mastectomy pain; central pain; spinal cord injury pain;
post-stroke pain; thalamic pain; complex regional pain syndrome;
phantom pain; intractable pain; acute pain, acute post-operative
pain; acute musculoskeletal pain; joint pain; mechanical low back
pain; neck pain; tendonitis; injury pain; exercise pain; acute
visceral pain; pyelonephritis; appendicitis; cholecystitis;
intestinal obstruction; hernias; chest pain, cardiac pain; pelvic
pain, renal colic pain, acute obstetric pain, labor pain; cesarean
section pain; acute inflammatory pain, burn pain, trauma pain;
acute intermittent pain, endometriosis; acute herpes zoster pain;
sickle cell anemia; acute pancreatitis; breakthrough pain;
orofacial pain; sinusitis pain; dental pain; multiple sclerosis
(MS) pain; pain in depression; leprosy pain; Behcet's disease pain;
adiposis dolorosa; phlebitic pain; Guillain-Barre pain; painful
legs and moving toes; Haglund syndrome; erythromelalgia pain;
Fabry's disease pain; bladder and urogenital disease; urinary
incontinence, pathological cough; hyperactive bladder; painful
bladder syndrome; interstitial cystitis (IC); prostatitis; complex
regional pain syndrome (CRPS), type I, complex regional pain
syndrome (CRPS) type II; widespread pain, paroxysmal extreme pain,
pruritus, tinnitus, or angina-induced pain.
Manufacture of Medicaments
In another aspect, the invention provides the use of a compound of
the invention, or a pharmaceutically acceptable salt or
pharmaceutical composition thereof, for the manufacture of a
medicament.
In another aspect, the invention provides the use of a compound of
the invention, a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition thereof for the manufacture of a
medicament for use in inhibiting a voltage-gated sodium channel. In
another aspect, the voltage-gated sodium channel is
Na.sub.V1.8.
In yet another aspect, the invention provides the use of a compound
of the invention, a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition thereof for the manufacture of a
medicament for use in treating or lessening the severity in a
subject of chronic pain, gut pain, neuropathic pain,
musculoskeletal pain, acute pain, inflammatory pain, cancer pain,
idiopathic pain, postsurgical pain (e.g., bunionectomy pain or
abdominoplasty pain), visceral pain, multiple sclerosis,
Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or
cardiac arrhythmia.
In yet another aspect, the invention provides the use of a compound
of the invention, a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition thereof for the manufacture of a
medicament for use in treating or lessening the severity in a
subject of chronic pain, gut pain, neuropathic pain,
musculoskeletal pain, acute pain, inflammatory pain, cancer pain,
idiopathic pain, postsurgical pain, bunionectomy pain, multiple
sclerosis, Charcot-Marie-Tooth syndrome, incontinence, or cardiac
arrhythmia.
In yet another aspect, the invention provides the use of the
compound, pharmaceutically acceptable salt, or pharmaceutical
composition described herein for the manufacture of a medicament
for use in treating or lessening the severity in a subject of gut
pain, wherein gut pain comprises inflammatory bowel disease pain,
Crohn's disease pain or interstitial cystitis pain.
In yet another aspect, the invention provides a compound of the
invention, a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition thereof for the manufacture of a
medicament for use in treating or lessening the severity in a
subject of neuropathic pain. In some aspects, the neuropathic pain
comprises post-herpetic neuralgia or idiopathic small-fiber
neuropathy.
In yet another aspect, the invention provides the use of a compound
of the invention, a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition thereof for the manufacture of a
medicament for use in a treating or lessening the severity in a
subject of neuropathic pain, wherein neuropathic pain comprises
post-herpetic neuralgia, diabetic neuralgia, painful HIV-associated
sensory neuropathy, trigeminal neuralgia, burning mouth syndrome,
post-amputation pain, phantom pain, painful neuroma; traumatic
neuroma; Morton's neuroma; nerve entrapment injury, spinal
stenosis, carpal tunnel syndrome, radicular pain, sciatica pain;
nerve avulsion injury, brachial plexus avulsion injury; complex
regional pain syndrome, drug therapy induced neuralgia, cancer
chemotherapy induced neuralgia, anti-retroviral therapy induced
neuralgia; post spinal cord injury pain, idiopathic small-fiber
neuropathy, idiopathic sensory neuropathy or trigeminal autonomic
neuropathy.
In yet another aspect, the invention provides the use of a compound
of the invention, a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition thereof for the manufacture of a
medicament for use in treating or lessening the severity in a
subject of musculoskeletal pain. In some aspects the
musculoskeletal pain comprises osteoarthritis pain.
In yet another aspect, the invention provides the use of a compound
of the invention, a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition thereof for the manufacture of a
medicament for use in treating or lessening the severity in a
subject of musculoskeletal pain, wherein musculoskeletal pain
comprises osteoarthritis pain, back pain, cold pain, burn pain or
dental pain.
In yet another aspect, the invention provides the use of a compound
of the invention, a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition thereof for the manufacture of a
medicament for use in treating or lessening the severity in a
subject of inflammatory pain, wherein inflammatory pain comprises
rheumatoid arthritis pain or vulvodynia.
In yet another aspect, the invention provides the use of a compound
of the invention, a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition thereof for the manufacture of a
medicament for use in treating or lessening the severity in a
subject of inflammatory pain, wherein inflammatory pain comprises
rheumatoid arthritis pain.
In yet another aspect, the invention provides the use of a compound
of the invention, a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition thereof for the manufacture of a
medicament for use in treating or lessening the severity in a
subject of idiopathic pain, wherein idiopathic pain comprises
fibromyalgia pain.
In yet another aspect, the invention provides the use of a compound
of the invention, a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition thereof for the manufacture of a
medicament for use in treating or lessening the severity in a
subject of pathological cough.
In yet another aspect, the invention provides the use of a compound
of the invention, a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition thereof for the manufacture of a
medicament for use in treating or lessening the severity in a
subject of acute pain. In some aspects, the acute pain comprises
acute post-operative pain.
In yet another aspect, the invention provides the use of a compound
of the invention, a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition thereof for the manufacture of a
medicament for use in treating or lessening the severity in a
subject of postsurgical pain (e.g., bunionectomy pain or
abdominoplasty pain).
In yet another aspect, the invention provides the use of a compound
of the invention, a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition thereof for the manufacture of a
medicament for use in treating or lessening the severity in a
subject of bunionectomy pain.
In yet another aspect, the invention provides the use of a compound
of the invention, a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition thereof for the manufacture of a
medicament for use in treating or lessening the severity in a
subject of abdominoplasty pain.
In yet another aspect, the invention provides the use of a compound
of the invention, a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition thereof for the manufacture of a
medicament for use in treating or lessening the severity in a
subject of visceral pain. In some aspects, the visceral pain
comprises visceral pain from abdominoplasty.
In yet another aspect, the invention provides the use of a compound
of the invention, a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition thereof for the manufacture of a
medicament for use in combination with one or more additional
therapeutic agents administered concurrently with, prior to, or
subsequent to treatment with the compound or pharmaceutical
composition. In some embodiments, the additional therapeutic agent
is a sodium channel inhibitor.
In another aspect, the invention provides the use of a compound of
the invention, a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition thereof for the manufacture of a
medicament for use in treating or lessening the severity of acute
pain, chronic pain, neuropathic pain, inflammatory pain, arthritis,
migraine, cluster headaches, trigeminal neuralgia, herpetic
neuralgia, general neuralgias, epilepsy, epilepsy conditions,
neurodegenerative disorders, psychiatric disorders, anxiety,
depression, bipolar disorder, myotonia, arrhythmia, movement
disorders, neuroendocrine disorders, ataxia, multiple sclerosis,
irritable bowel syndrome, incontinence, pathological cough,
visceral pain, osteoarthritis pain, postherpetic neuralgia,
diabetic neuropathy, radicular pain, sciatica, back pain, head
pain, neck pain, severe pain, intractable pain, nociceptive pain,
breakthrough pain, postsurgical pain (e.g., bunionectomy pain or
abdominoplasty pain), cancer pain, stroke, cerebral ischemia,
traumatic brain injury, amyotrophic lateral sclerosis, stress
induced angina, exercise induced angina, palpitations,
hypertension, or abnormal gastro-intestinal motility.
In another aspect, the invention provides the use of a compound of
the invention, a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition thereof for the manufacture of a
medicament for use in treating or lessening the severity of femur
cancer pain; non-malignant chronic bone pain; rheumatoid arthritis;
osteoarthritis; spinal stenosis; neuropathic low back pain;
myofascial pain syndrome; fibromyalgia; temporomandibular joint
pain; chronic visceral pain, abdominal pain; pancreatic pain; IBS
pain; chronic and acute headache pain; migraine; tension headache;
cluster headaches; chronic and acute neuropathic pain,
post-herpetic neuralgia; diabetic neuropathy; HIV-associated
neuropathy; trigeminal neuralgia; Charcot-Marie-Tooth neuropathy;
hereditary sensory neuropathy; peripheral nerve injury; painful
neuromas; ectopic proximal and distal discharges; radiculopathy;
chemotherapy induced neuropathic pain; radiotherapy-induced
neuropathic pain; post-mastectomy pain; central pain; spinal cord
injury pain; post-stroke pain; thalamic pain; complex regional pain
syndrome; phantom pain; intractable pain; acute pain, acute
post-operative pain; acute musculoskeletal pain; joint pain;
mechanical low back pain; neck pain; tendonitis; injury pain;
exercise pain; acute visceral pain; pyelonephritis; appendicitis;
cholecystitis; intestinal obstruction; hernias; chest pain, cardiac
pain; pelvic pain, renal colic pain, acute obstetric pain, labor
pain; cesarean section pain; acute inflammatory, burn pain, trauma
pain; acute intermittent pain, endometriosis; acute herpes zoster
pain; sickle cell anemia; acute pancreatitis; breakthrough pain;
orofacial pain; sinusitis pain; dental pain; multiple sclerosis
(MS) pain; pain in depression; leprosy pain; Behcet's disease pain;
adiposis dolorosa; phlebitic pain; Guillain-Barre pain; painful
legs and moving toes; Haglund syndrome; erythromelalgia pain;
Fabry's disease pain; bladder and urogenital disease; urinary
incontinence; pathological cough; hyperactive bladder; painful
bladder syndrome; interstitial cystitis (IC); prostatitis; complex
regional pain syndrome (CRPS) type I; complex regional pain
syndrome (CRPS) type II; widespread pain, paroxysmal extreme pain,
pruritus, tinnitus, or angina-induced pain.
Administration of Pharmaceutically Acceptable Salts and
Compositions.
In certain embodiments of the invention an "effective amount" of a
compound of the invention, a pharmaceutically acceptable salt
thereof, or a pharmaceutical composition thereof is that amount
effective for treating or lessening the severity of one or more of
the conditions recited above.
The compounds, salts, and compositions, according to the method of
the invention, may be administered using any amount and any route
of administration effective for treating or lessening the severity
of one or more of the pain or non-pain diseases recited herein. The
exact amount required will vary from subject to subject, depending
on the species, age, and general condition of the subject, the
severity of the condition, the particular agent, its mode of
administration, and the like. The compounds, salts, and
compositions of the invention are preferably formulated in dosage
unit form for ease of administration and uniformity of dosage. The
expression "dosage unit form" as used herein refers to a physically
discrete unit of agent appropriate for the subject to be treated.
It will be understood, however, that the total daily usage of the
compounds, salts, and compositions of the invention will be decided
by the attending physician within the scope of sound medical
judgment. The specific effective dose level for any particular
subject or organism will depend upon a variety of factors including
the disorder being treated and the severity of the disorder; the
activity of the specific compound or salt employed; the specific
composition employed; the age, body weight, general health, sex and
diet of the subject; the time of administration, route of
administration, and rate of excretion of the specific compound or
salt employed; the duration of the treatment; drugs used in
combination or coincidental with the specific compound or salt
employed, and like factors well known in the medical arts. The term
"subject" or "patient," as used herein, means an animal, preferably
a mammal, and most preferably a human.
The pharmaceutically acceptable compositions of this invention can
be administered to humans and other animals orally, rectally,
parenterally, intracisternally, intravaginally, intraperitoneally,
topically (as by powders, ointments, or drops), bucally, as an oral
or nasal spray, or the like, depending on the severity of the
condition being treated. In certain embodiments, the compound,
salts, and compositions of the invention may be administered orally
or parenterally at dosage levels of about 0.001 mg/kg to about 100
mg/kg, or about 0.01 mg/kg to about 50 mg/kg, of subject body
weight per day, one or more times a day, effective to obtain the
desired therapeutic effect.
Liquid dosage forms for oral administration include, but are not
limited to, pharmaceutically acceptable emulsions, microemulsions,
solutions, suspensions, syrups and elixirs. In addition to the
active compound or salt, the liquid dosage forms may contain inert
diluents commonly used in the art such as, for example, water or
other solvents, solubilizing agents and emulsifiers such as ethyl
alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl
alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol,
dimethylformamide, oils (in particular, cottonseed, groundnut,
corn, germ, olive, castor, and sesame oils), glycerol,
tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid
esters of sorbitan, and mixtures thereof. Besides inert diluents,
the oral compositions can also include adjuvants such as wetting
agents, emulsifying and suspending agents, sweetening, flavoring,
and perfuming agents.
Injectable preparations, for example, sterile injectable aqueous or
oleaginous suspensions may be formulated according to the known art
using suitable dispersing or wetting agents and suspending agents.
The sterile injectable preparation may also be a sterile injectable
solution, suspension or emulsion in a nontoxic parenterally
acceptable diluent or solvent, for example, as a solution in
1,3-butanediol. Among the acceptable vehicles and solvents that may
be employed are water, Ringer's solution, U.S.P. and isotonic
sodium chloride solution. In addition, sterile, fixed oils are
conventionally employed as a solvent or suspending medium. For this
purpose any bland fixed oil can be employed including synthetic
mono- or diglycerides. In addition, fatty acids such as oleic acid
are used in the preparation of injectables.
The injectable formulations can be sterilized, for example, by
filtration through a bacterial-retaining filter, or by
incorporating sterilizing agents in the form of sterile solid
compositions which can be dissolved or dispersed in sterile water
or other sterile injectable medium prior to use.
In order to prolong the effect of the compounds of the invention,
it is often desirable to slow the absorption of the compounds from
subcutaneous or intramuscular injection. This may be accomplished
by the use of a liquid suspension of crystalline or amorphous
material with poor water solubility. The rate of absorption of the
compound then depends upon its rate of dissolution that, in turn,
may depend upon crystal size and crystalline form. Alternatively,
delayed absorption of a parenterally administered compound form is
accomplished by dissolving or suspending the compound in an oil
vehicle. Injectable depot forms are made by forming microencapsule
matrices of the compound in biodegradable polymers such as
polylactide-polyglycolide. Depending upon the ratio of compound to
polymer and the nature of the particular polymer employed, the rate
of compound release can be controlled. Examples of other
biodegradable polymers include poly(orthoesters) and
poly(anhydrides). Depot injectable formulations are also prepared
by entrapping the compound in liposomes or microemulsions that are
compatible with body tissues.
Compositions for rectal or vaginal administration are preferably
suppositories which can be prepared by mixing the compound or salt
of this invention with suitable non-irritating excipients or
carriers such as cocoa butter, polyethylene glycol or a suppository
wax which are solid at ambient temperature but liquid at body
temperature and therefore melt in the rectum or vaginal cavity and
release the active compound.
Solid dosage forms for oral administration include capsules,
tablets, pills, powders, and granules. In such solid dosage forms,
the active compound or salt is mixed with at least one inert,
pharmaceutically acceptable excipient or carrier such as sodium
citrate or dicalcium phosphate and/or a) fillers or extenders such
as starches, lactose, sucrose, glucose, mannitol, and silicic acid,
b) binders such as, for example, carboxymethylcellulose, alginates,
gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants
such as glycerol, d) disintegrating agents such as agar-agar,
calcium carbonate, potato or tapioca starch, alginic acid, certain
silicates, and sodium carbonate, e) solution retarding agents such
as paraffin, f) absorption accelerators such as quaternary ammonium
compounds, g) wetting agents such as, for example, cetyl alcohol
and glycerol monostearate, h) absorbents such as kaolin and
bentonite clay, and i) lubricants such as talc, calcium stearate,
magnesium stearate, solid polyethylene glycols, sodium lauryl
sulfate, and mixtures thereof. In the case of capsules, tablets and
pills, the dosage form may also comprise buffering agents.
Solid compositions of a similar type may also be employed as
fillers in soft and hard-filled gelatin capsules using such
excipients as lactose or milk sugar as well as high molecular
weight polyethylene glycols and the like. The solid dosage forms of
tablets, dragees, capsules, pills, and granules can be prepared
with coatings and shells such as enteric coatings and other
coatings well known in the pharmaceutical formulating art. They may
optionally contain opacifying agents and can also be of a
composition that they release the active ingredient(s) only, or
preferentially, in a certain part of the intestinal tract,
optionally, in a delayed manner. Examples of embedding compositions
that can be used include polymeric substances and waxes. Solid
compositions of a similar type may also be employed as fillers in
soft and hard-filled gelatin capsules using such excipients as
lactose or milk sugar as well as high molecular weight polyethylene
glycols and the like.
The active compound or salt can also be in microencapsulated form
with one or more excipients as noted above. The solid dosage forms
of tablets, dragees, capsules, pills, and granules can be prepared
with coatings and shells such as enteric coatings, release
controlling coatings and other coatings well known in the
pharmaceutical formulating art. In such solid dosage forms the
active compound or salt may be admixed with at least one inert
diluent such as sucrose, lactose or starch. Such dosage forms may
also comprise, as is normal practice, additional substances other
than inert diluents, e.g., tableting lubricants and other tableting
aids such a magnesium stearate and microcrystalline cellulose. In
the case of capsules, tablets and pills, the dosage forms may also
comprise buffering agents. They may optionally contain opacifying
agents and can also be of a composition that they release the
active ingredient(s) only, or preferentially, in a certain part of
the intestinal tract, optionally, in a delayed manner. Examples of
embedding compositions that can be used include polymeric
substances and waxes.
Dosage forms for topical or transdermal administration of a
compound or salt of this invention include ointments, pastes,
creams, lotions, gels, powders, solutions, sprays, inhalants or
patches. The active component is admixed under sterile conditions
with a pharmaceutically acceptable carrier and any needed
preservatives or buffers as may be required. Ophthalmic
formulation, eardrops, and eye drops are also contemplated as being
within the scope of this invention. Additionally, the invention
contemplates the use of transdermal patches, which have the added
advantage of providing controlled delivery of a compound to the
body. Such dosage forms are prepared by dissolving or dispensing
the compound in the proper medium. Absorption enhancers can also be
used to increase the flux of the compound across the skin. The rate
can be controlled by either providing a rate controlling membrane
or by dispersing the compound in a polymer matrix or gel.
As described generally above, the compounds of the invention are
useful as inhibitors of voltage-gated sodium channels. In one
embodiment, the compounds are inhibitors of Na.sub.V1.8 and thus,
without wishing to be bound by any particular theory, the
compounds, salts, and compositions are particularly useful for
treating or lessening the severity of a disease, condition, or
disorder where activation or hyperactivity of Na.sub.V1.8 is
implicated in the disease, condition, or disorder. When activation
or hyperactivity of Na.sub.V1.8 is implicated in a particular
disease, condition, or disorder, the disease, condition, or
disorder may also be referred to as a "Na.sub.V1.8-mediated
disease, condition or disorder." Accordingly, in another aspect,
the invention provides a method for treating or lessening the
severity of a disease, condition, or disorder where activation or
hyperactivity of Na.sub.V1.8 is implicated in the disease
state.
The activity of a compound utilized in this invention as an
inhibitor of Na.sub.V1.8 may be assayed according to methods
described generally in International Publication No. WO 2014/120808
A9 and U.S. Publication No. 2014/0213616 A1, both of which are
incorporated by reference in their entirety, methods described
herein, and other methods known and available to one of ordinary
skill in the art.
Additional Therapeutic Agents
It will also be appreciated that the compounds, salts, and
pharmaceutically acceptable compositions of the invention can be
employed in combination therapies, that is, the compounds, salts,
and pharmaceutically acceptable compositions can be administered
concurrently with, prior to, or subsequent to, one or more other
desired therapeutics or medical procedures. The particular
combination of therapies (therapeutics or procedures) to employ in
a combination regimen will take into account compatibility of the
desired therapeutics and/or procedures and the desired therapeutic
effect to be achieved. It will also be appreciated that the
therapies employed may achieve a desired effect for the same
disorder (for example, an inventive compound may be administered
concurrently with another agent used to treat the same disorder),
or they may achieve different effects (e.g., control of any adverse
effects). As used herein, additional therapeutic agents that are
normally administered to treat or prevent a particular disease, or
condition, are known as "appropriate for the disease, or condition,
being treated." For example, exemplary additional therapeutic
agents include, but are not limited to: nonopioid analgesics
(indoles such as Etodolac, Indomethacin, Sulindac, Tolmetin;
naphthylalkanones such as Nabumetone; oxicams such as Piroxicam;
para-aminophenol derivatives, such as Acetaminophen; propionic
acids such as Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen,
Naproxen, Naproxen sodium, Oxaprozin; salicylates such as Aspirin,
Choline magnesium trisalicylate, Diflunisal; fenamates such as
meclofenamic acid, Mefenamic acid; and pyrazoles such as
Phenylbutazone); or opioid (narcotic) agonists (such as Codeine,
Fentanyl, Hydromorphone, Levorphanol, Meperidine, Methadone,
Morphine, Oxycodone, Oxymorphone, Propoxyphene, Buprenorphine,
Butorphanol, Dezocine, Nalbuphine, and Pentazocine). Additionally,
nondrug analgesic approaches may be utilized in conjunction with
administration of one or more compounds of the invention. For
example, anesthesiologic (intraspinal infusion, neural blockade),
neurosurgical (neurolysis of CNS pathways), neurostimulatory
(transcutaneous electrical nerve stimulation, dorsal column
stimulation), physiatric (physical therapy, orthotic devices,
diathermy), or psychologic (cognitive methods-hypnosis,
biofeedback, or behavioral methods) approaches may also be utilized
Additional appropriate therapeutic agents or approaches are
described generally in The Merck Manual, Nineteenth Edition, Ed.
Robert S. Porter and Justin L. Kaplan, Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc., 2011, and the Food
and Drug Administration website, www.fda.gov, the entire contents
of which are hereby incorporated by reference.
In another embodiment, additional appropriate therapeutic agents
are selected from the following:
(1) an opioid analgesic, e.g. morphine, heroin, hydromorphone,
oxymorphone, levorphanol, levallorphan, methadone, meperidine,
fentanyl, cocaine, codeine, dihydrocodeine, oxycodone, hydrocodone,
propoxyphene, nalmefene, nalorphine, naloxone, naltrexone,
buprenorphine, butorphanol, nalbuphine or pentazocine;
(2) a nonsteroidal antiinflammatory drug (NSAID), e.g. aspirin,
diclofenac, diflunisal, etodolac, fenbufen, fenoprofen, flufenisal,
flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac,
meclofenamic acid, mefenamic acid, meloxicam, nabumetone, naproxen,
nimesulide, nitroflurbiprofen, olsalazine, oxaprozin,
phenylbutazone, piroxicam, sulfasalazine, sulindac, tolmetin or
zomepirac;
(3) a barbiturate sedative, e.g. amobarbital, aprobarbital,
butabarbital, butalbital, mephobarbital, metharbital, methohexital,
pentobarbital, phenobarbital, secobarbital, talbutal, thiamylal or
thiopental;
(4) a benzodiazepine having a sedative action, e.g.
chlordiazepoxide, clorazepate, diazepam, flurazepam, lorazepam,
oxazepam, temazepam or triazolam;
(5) a histamine (H.sub.1) antagonist having a sedative action, e.g.
diphenhydramine, pyrilamine, promethazine, chlorpheniramine or
chlorcyclizine;
(6) a sedative such as glutethimide, meprobamate, methaqualone or
dichloralphenazone;
(7) a skeletal muscle relaxant, e.g. baclofen, carisoprodol,
chlorzoxazone, cyclobenzaprine, methocarbamol or orphenadrine;
(8) an NMDA receptor antagonist, e.g. dextromethorphan
((+)-3-hydroxy-N-methylmorphinan) or its metabolite dextrorphan
((+)-3-hydroxy-N-methylmorphinan), ketamine, memantine,
pyrroloquinoline quinine,
cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid, budipine,
EN-3231 (MorphiDex.RTM.), a combination formulation of morphine and
dextromethorphan), topiramate, neramexane or perzinfotel including
an NR2B antagonist, e.g. ifenprodil, traxoprodil or
(-)-(R)-6-{2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl--
3,4-dihydro-2(1H)-quinolinone;
(9) an alpha-adrenergic, e.g. doxazosin, tamsulosin, clonidine,
guanfacine, dexmedetomidine, modafinil, or
4-amino-6,7-dimethoxy-2-(5-methane-sulfonamido-1,
2,3,4-tetrahydroisoquinolin-2-yl)-5-(2-pyridyl) quinazoline;
(10) a tricyclic antidepressant, e.g. desipramine, imipramine,
amitriptyline or nortriptyline;
(11) an anticonvulsant, e.g. carbamazepine (Tegretol.RTM.),
lamotrigine, topiramate, lacosamide (Vimpat.RTM.) or valproate;
(12) a tachykinin (NK) antagonist, particularly an NK-3, NK-2 or
NK-1 antagonist, e.g.
(alphaR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-met-
hyl-5-(4-methylphenyl)-7H-[1,4]diazocino[2,1-g][1,7]-naphthyridine-6-13-di-
one (TAK-637),
5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorop-
henyl)-4-morpholinyl]-methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one
(MK-869), aprepitant, lanepitant, dapitant or
3-[[2-methoxy-5-(trifluoromethoxy)phenyl]-methylamino]-2-phenylpiperidine
(2S,3S);
(13) a muscarinic antagonist, e.g oxybutynin, tolterodine,
propiverine, tropsium chloride, darifenacin, solifenacin,
temiverine and ipratropium;
(14) a COX-2 selective inhibitor, e.g. celecoxib, rofecoxib,
parecoxib, valdecoxib, deracoxib, etoricoxib, or lumiracoxib;
(15) a coal-tar analgesic, in particular paracetamol;
(16) a neuroleptic such as droperidol, chlorpromazine, haloperidol,
perphenazine, thioridazine, mesoridazine, trifluoperazine,
fluphenazine, clozapine, olanzapine, risperidone, ziprasidone,
quetiapine, sertindole, aripiprazole, sonepiprazole, blonanserin,
iloperidone, perospirone, raclopride, zotepine, bifeprunox,
asenapine, lurasidone, amisulpride, balaperidone, palindore,
eplivanserin, osanetant, rimonabant, meclinertant, Miraxion.RTM. or
sarizotan;
(17) a vanilloid receptor agonist (e.g. resinferatoxin or civamide)
or antagonist (e.g. capsazepine, GRC-15300);
(18) a beta-adrenergic such as propranolol;
(19) a local anaesthetic such as mexiletine;
(20) a corticosteroid such as dexamethasone;
(21) a 5-HT receptor agonist or antagonist, particularly a
5-HT.sub.1B/1D agonist such as eletriptan, sumatriptan,
naratriptan, zolmitriptan or rizatriptan;
(22) a 5-HT.sub.2A receptor antagonist such as
R(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidin-
emethanol (MDL-100907);
(23) a cholinergic (nicotinic) analgesic, such as ispronicline
(TC-1734), (E)-N-methyl-4-(3-pyridinyl)-3-buten-1-amine (RJR-2403),
(R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594) or
nicotine;
(24) Tramadol.RTM., Tramadol ER (Ultram ER.RTM.), Tapentadol ER
(Nucynta.RTM.);
(25) a PDE5 inhibitor, such as
5-[2-ethoxy-5-(4-methyl-1-piperazinyl-sulphonyl)phenyl]-1-methyl-3-n-prop-
yl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil),
(6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)--
pyrazino[2',1':6,1]-pyrido[3,4-b]indole-1,4-dione (IC-351 or
tadalafil),
2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-pro-
pyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (vardenafil),
5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-di-
hydro-7H-pyrazolo[4,3-d]pyrimidin-7-one,
5-(5-acetyl-2-propoxy-3-pyridinyl)-3-ethyl-2-(1-isopropyl-3-azetidinyl)-2-
,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one,
5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2--
methoxyethyl]-2,6-dihydro-7H-pymzolo[4,3-d]pyrimidin-7-one,
4-[(3-chloro-4-methoxybenzyl)amino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-
-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide,
3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)--
N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide;
(26) an alpha-2-delta ligand such as gabapentin (Neurontin.RTM.),
gabapentin GR (Gralise.RTM.), gabapentin, enacarbil
(Horizant.RTM.), pregabalin (Lyrica.RTM.), 3-methyl gabapentin,
(1[alpha],3 [alpha],5
[alpha])(3-amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid, (3
S,5R)-3-aminomethyl-5-methyl-heptanoic acid, (3
S,5R)-3-amino-5-methyl-heptanoic acid, (3
S,5R)-3-amino-5-methyl-octanoic acid,
(2S,4S)-4-(3-chlorophenoxy)proline,
(2S,4S)-4-(3-fluorobenzyl)-proline,
[(1R,5R,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid,
3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one,
C-[1-(1H-tetrazol-5-ylmethyl)-cycloheptyl]-methylamine,
(3S,4S)-(1-aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid, (3
S,5R)-3-aminomethyl-5-methyl-octanoic acid, (3
S,5R)-3-amino-5-methyl-nonanoic acid,
(3S,5R)-3-amino-5-methyl-octanoic acid,
(3R,4R,5R)-3-amino-4,5-dimethyl-heptanoic acid and
(3R,4R,5R)-3-amino-4,5-dimethyl-octanoic acid;
(27) a cannabinoid such as KHK-6188;
(28) metabotropic glutamate subtype 1 receptor (mGluR1)
antagonist;
(29) a serotonin reuptake inhibitor such as sertraline, sertraline
metabolite demethylsertraline, fluoxetine, norfluoxetine
(fluoxetine desmethyl metabolite), fluvoxamine, paroxetine,
citalopram, citalopram metabolite desmethylcitalopram,
escitalopram, d,1-fenfluramine, femoxetine, ifoxetine,
cyanodothiepin, litoxetine, dapoxetine, nefazodone, cericlamine and
trazodone;
(30) a noradrenaline (norepinephrine) reuptake inhibitor, such as
maprotiline, lofepramine, mirtazepine, oxaprotiline, fezolamine,
tomoxetine, mianserin, bupropion, bupropion metabolite
hydroxybupropion, nomifensine and viloxazine (Vivalan.RTM.),
especially a selective noradrenaline reuptake inhibitor such as
reboxetine, in particular (S,S)-reboxetine;
(31) a dual serotonin-noradrenaline reuptake inhibitor, such as
venlafaxine, venlafaxine metabolite O-desmethylvenlafaxine,
clomipramine, clomipramine metabolite desmethylclomipramine,
duloxetine (Cymbalta.RTM.), milnacipran and imipramine;
(32) an inducible nitric oxide synthase (iNOS) inhibitor such as
S-[2-[(1-iminoethyl)amino]ethyl]-L-homocysteine,
S-[2[(1-iminoethyl)-amino]ethyl]-4,4-dioxo-L-cysteine,
S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-L-cysteine,
(2S,5Z)-2-amino-2-methyl-7-[(1-iminoethyl)amino]-5-heptenoic acid,
2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)-butyl]thio]-S-chloro-S-pyri-
dinecarbonitrile;
2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-4-chlorobenzonit-
rile,
(2S,4R)-2-amino-4-[[2-chloro-5-(trifluoromethyl)phenyl]thio]-5-thiaz-
olebutanol, 2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)
butyl]thio]-6-(trifluoromethyl)-3-pyridinecarbonitrile,
2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-5-chlorobenzonit-
rile,
N-[4-[2-(3-chlorobenzylamino)ethyl]phenyl]thiophene-2-carboxamidine,
NXN-462, or guanidinoethyldisulfide;
(33) an acetylcholinesterase inhibitor such as donepezil;
(34) a prostaglandin E2 subtype 4 (EP4) antagonist such as
N-[({2-[4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethy-
l}amino)-carbonyl]-4-methylbenzenesulfonamide or
4-[(15)-1-({[5-chloro-2-(3-fluorophenoxy)pyridin-3-yl]carbonyl}amino)ethy-
l]benzoic acid;
(35) a leukotriene B4 antagonist; such as
1-(3-biphenyl-4-ylmethyl-4-hydroxy-chroman-7-yl)-cyclopentanecarboxylic
acid (CP-105696),
5-[2-(2-Carboxyethyl)-3-[6-(4-methoxyphenyl)-5E-hexenyl]oxyphenoxy]-valer-
ic acid (ONO-4057) or DPC-11870;
(36) a 5-lipoxygenase inhibitor, such as zileuton,
6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl])phenoxy-methy-
l]-1-methyl-2-quinolone (ZD-2138), or
2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone (CV-6504);
(37) a sodium channel blocker, such as lidocaine, lidocaine plus
tetracaine cream (ZRS-201) or eslicarbazepine acetate;
(38) an Na.sub.V1.7 blocker, such as XEN-402, XEN403, TV-45070,
PF-05089771, CNV1014802, GDC-0276, RG7893 and such as those
disclosed in WO2011/140425 (US2011/306607); WO2012/106499
(US2012196869); WO2012/112743 (US2012245136); WO2012/125613
(US2012264749), WO2012/116440 (US2014187533), WO2011026240
(US2012220605), U.S. Pat. Nos. 8,883,840, 8,466,188, or
WO2013/109521 (US2015005304), the entire contents of each
application hereby incorporated by reference.
(38a) an Na.sub.V1.7 blocker such as
(2-benzylspiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl)--
(4-isopropoxy-3-methyl-phenyl)methanone,
2,2,2-trifluoro-1-[1'-[3-methoxy-4-[2-(trifluoromethoxy)ethoxy]benzoyl]-2-
,4-dimethyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]-
ethanone,
[8-fluoro-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1-
,2-a]pyrazine-1,4'-piperidine]-1'-yl]-(4-isobutoxy-3-methoxy-phenyl)methan-
one,
1-(4-benzhydrylpiperazin-1-yl)-3-[2-(3,4-dimethylphenoxy)ethoxy]propa-
n-2-ol,
(4-butoxy-3-methoxy-phenyl)-[2-methyl-6-(trifluoromethyl)spiro[3,4-
-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl]methanone,
[8-fluoro-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyra-
zine-1,4'-piperidine]-1'-yl]-(5-isopropoxy-6-methyl-2-pyridyl)methanone,
(4-isopropoxy-3-methyl-phenyl)-[2-methyl-6-(1,1,2,2,2-pentafluoroethyl)sp-
iro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl]methanone,
5-[2-methyl-4-[2-methyl-6-(2,2,2-trifluoroacetyl)spiro[3,4-dihydropyrrolo-
[1,2-a]pyrazine-1,4'-piperidine]-1'-carbonyl]phenyl]pyridine-2-carbonitril-
e,
(4-isopropoxy-3-methyl-phenyl)-[6-(trifluoromethyl)spiro[3,4-dihydro-2H-
-pyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl]methanone,
2,2,2-trifluoro-1-[1'-[3-methoxy-4-[2-(trifluoromethoxy)ethoxy]benzoyl]-2-
-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]etha-
none,
2,2,2-trifluoro-1-[1'-(5-isopropoxy-6-methyl-pyridine-2-carbonyl)-3,-
3-dimethyl-spiro[2,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]e-
thanone,
2,2,2-trifluoro-1-[1'-(5-isopentyloxypyridine-2-carbonyl)-2-methy-
l-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]ethanone,
(4-isopropoxy-3-methoxy-phenyl)-[2-methyl-6-(trifluoromethyl)spiro[3,4-di-
hydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl]methanone,
2,2,2-trifluoro-1-[1'-(5-isopentyloxypyridine-2-carbonyl)-2,4-dimethyl-sp-
iro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]ethanone,
1-[(3S)-2,3-dimethyl-1'-[4-(3,3,3-trifluoropropoxymethy)benzoyl]spiro[3,4-
-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]-2,2,2-trifluoro-etha-
none,
[8-fluoro-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a-
]pyrazine-1,4'-piperidine]-1'-yl]-[3-methoxy-4-[(1R)-1-methylpropoxy]pheny-
l]methanone,
2,2,2-trifluoro-1-[1'-(5-isopropoxy-6-methyl-pyridine-2-carbonyl)-2,4-dim-
ethyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]ethano-
ne,
1-[1'-[4-methoxy-3-(trifluoromethyl)benzoyl]-2-methyl-spiro[3,4-dihydr-
opyrrolo[1,2-a]pyrazine-1,4'-piperidine]-6-yl]-2,2-dimethyl-propan-1-one,
(4-isopropoxy-3-methyl-phenyl)-[2-methyl-6-(trifluoromethyl)spiro[3,4-dih-
ydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl]methanone,
[2-methyl-6-(1-methylcyclopropanecarbonyl)spiro[3,4-dihydropyrrolo[1,2-a]-
pyrazine-1,4'-piperidine]-1'-yl]-[4-(3,3,3-trifluoropropoxymethyl)phenyl]m-
ethanone,
4-bromo-N-(4-bromophenyl)-3-[(1-methyl-2-oxo-4-piperidyl)sulfamo-
yl]benzamide or
(3-chloro-4-isopropoxy-phenyl)-[2-methyl-6-(1,1,2,2,2-pentafluoroethyl)sp-
iro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4'-piperidine]-1'-yl]methanone.
(39) an Na.sub.V1.8 blocker, such as PF-04531083, PF-06372865 and
such as those disclosed in WO2008/135826 (US2009048306),
WO2006/011050 (US2008312235), WO2013/061205 (US2014296313),
US20130303535, WO2013131018, U.S. Pat. No. 8,466,188, WO2013114250
(US2013274243), WO2014/120808 (US2014213616), WO2014/120815
(US2014228371) WO2014/120820 (US2014221435), WO2015/010065
(US20160152561), and WO2015/089361 (US20150166589), the entire
contents of each application hereby incorporated by reference.
(39a) an Na.sub.V1.8 blocker such as
4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridin-4--
yl)benzamide,
2-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-4-(perflu-
oroethyl)benzamide,
4,5-dichloro-2-(4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)benzami-
de,
4,5-dichloro-2-(3-fluoro-4-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridin-
-4-yl)benzamide,
2-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-5-(triflu-
oromethyl)benzamide,
N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(4-(trifluoromethoxy)phenoxy)-4-(trif-
luoromethyl)benzamide,
2-(4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-4-(perfluoroethyl)b-
enzamide,
5-chloro-2-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-1,2-dihydropyrid-
in-4-yl)benzamide,
N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(4-(trifluoromethoxy)phenoxy)-5-(trif-
luoromethyl)benzamide,
2-(4-fluoro-2-methylphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-5-(trifluo-
romethyl)benzamide,
2-(2-chloro-4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-5-(trifluo-
romethyl)benzamide,
5-chloro-2-(4-fluoro-2-methylphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)be-
nzamide,
4-chloro-2-(4-fluoro-2-methylphenoxy)-N-(2-oxo-1,2-dihydropyridin-
-4-yl)benzamide,
5-chloro-2-(2-chloro-4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)be-
nzamide,
2-((5-fluoro-2-hydroxybenzyl)oxy)-N-(2-oxo-1,2-dihydropyridin-4-y-
l)-4-(trifluoromethyl)benzamide,
N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(o-tolyloxy)-5-(trifluoromethyl)benza-
mide,
2-(2,4-difluorophenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-4-(trifluo-
romethyl)benzamide,
N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(2-(trifluoromethoxy)phenoxy)-5-(trif-
luoromethyl)benzamide,
2-(4-fluorophenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-5-(trifluoromethyl)-
benzamide. In one embodiment, the compound is
3-(4-fluoro-2-methoxyphenoxy)-N-(3-(methylsulfonyl)phenyl)quinoxaline-2-c-
arboxamide,
3-(2-chloro-4-fluorophenoxy)-N-(3-sulfamoylphenyl)quinoxaline-2-carboxami-
de,
3-(2-chloro-4-methoxyphenoxy)-N-(3-sulfamoylphenyl)quinoxaline-2-carbo-
xamide,
3-(4-chloro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)quinoxaline-2-c-
arboxamide,
4-(3-(4-(trifluoromethoxy)phenoxy)quinoxaline-2-carboxamido)picolinic
acid,
2-(2,4-difluorophenoxy)-N-(3-sulfamoylphenyl)quinoline-3-carboxamid-
e,
2-(4-fluoro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)quinoline-3-carboxam-
ide,
3-(2,4-difluorophenoxy)-N-(3-sulfamoylphenyl)quinoxaline-2-carboxamid-
e,
N-(3-sulfamoylphenyl)-2-(4-(trifluoromethoxy)phenoxy)quinoline-3-carbox-
amide,
N-(3-sulfamoylphenyl)-3-(4-(trifluoromethoxy)phenoxy)quinoxaline-2--
carboxamide,
3-(4-chloro-2-methylphenoxy)-N-(3-sulfamoylphenyl)quinoxaline-2-carboxami-
de,
5-(3-(4-(trifluoromethoxy)phenoxy)quinoxaline-2-carboxamido)picolinic
acid,
3-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-2,3-dihydro-1H-benzo[d]imida-
zol-5-yl)quinoxaline-2-carboxamide,
3-(4-fluoro-2-methoxyphenoxy)-N-(pyridin-4-yl)quinoxaline-2-carboxamide,
3-(4-fluorophenoxy)-N-(3-sulfamoylphenyl)quinoxaline-2-carboxamide,
N-(3-cyanophenyl)-3-(4-fluoro-2-methoxyphenoxy)quinoxaline-2-carboxamide,
N-(4-carbamoylphenyl)-3-(4-fluoro-2-methoxyphenoxy)quinoxaline-2-carboxam-
ide,
4-(3-(4-(trifluoromethoxy)phenoxy)quinoxaline-2-carboxamido)benzoic
acid,
N-(4-cyanophenyl)-3-(4-fluoro-2-methoxyphenoxy)quinoxaline-2-carbox-
amide,
5-(4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)benzamido)picolinic
acid,
5-(2-(2,4-dimethoxyphenoxy)-4,6-bis(trifluoromethyl)benzamido)picol-
inic acid,
4-(4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)benzamido)benzoic
acid,
5-(2-(4-fluoro-2-methoxyphenoxy)-4,6-bis(trifluoromethyl)benzamido)-
picolinic acid,
4-(2-(4-fluoro-2-methoxyphenoxy)-4-(perfluoroethyl)benzamido)benzoic
acid,
5-(2-(4-fluoro-2-methoxyphenoxy)-4-(perfluoroethyl)benzamido)picoli-
nic acid,
4-(2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamido)ben-
zoic acid,
5-(4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)benzamido)picolini- c
acid,
4-(2-(2-chloro-4-fluorophenoxy)-4-(perfluoroethyl)benzamido)benzoi-
c acid,
4-(2-(4-fluoro-2-methylphenoxy)-4-(perfluoroethyl)benzamido)benzoi-
c acid,
4-(4,5-dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamido)benzoic
acid, 4-(4,5-dichloro-2-(4-chloro-2-methylphenoxy)benzamido)benzoic
acid,
5-(4-(tert-butyl)-2-(4-fluoro-2-methoxyphenoxy)benzamido)picolinic
acid,
5-(4,5-dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamido)picolinic
acid, 4-(4,5-dichloro-2-(4-fluoro-2-methylphenoxy)benzamido)benzoic
acid, 5-(4,5-dichloro-2-(2,4-dimethoxyphenoxy)benzamido)picolinic
acid,
5-(4,5-dichloro-2-(2-chloro-4-fluorophenoxy)benzamido)picolinic
acid,
5-(4,5-dichloro-2-(4-fluoro-2-methylphenoxy)benzamido)picolinic
acid,
4-(4,5-dichloro-2-(4-chloro-2-methoxyphenoxy)benzamido)benzoic
acid, 5-(4,5-dichloro-2-(2,4-difluorophenoxy)benzamido)picolinic
acid,
2-(4-fluorophenoxy)-N-(3-sulfamoylphenyl)-5-(trifluoromethyl)benzamide,
2-(4-fluorophenoxy)-N-(3-sulfamoylphenyl)-4-(trifluoromethyl)benzamide,
2-(2-chloro-4-fluorophenoxy)-N-(3-sulfamoylphenyl)-5-(trifluoromethyl)ben-
zamide,
2-(4-fluorophenoxy)-N-(3-sulfamoylphenyl)-4-(trifluoromethyl)benza-
mide,
2-(2-chloro-4-fluorophenoxy)-N-(3-sulfamoylphenyl)-6-(trifluoromethy-
l)benzamide,
2-(2-chloro-4-fluorophenoxy)-5-(difluoromethyl)-N-(3-sulfamoylphenyl)benz-
amide,
2-(4-fluorophenoxy)-4-(perfluoroethyl)-N-(3-sulfamoylphenyl)benzami-
de,
2-(4-chloro-2-methoxyphenoxy)-4-(perfluoroethyl)-N-(3-sulfamoylphenyl)-
benzamide,
2-(4-fluoro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)-5-(trifluor-
omethyl)benzamide,
5-chloro-2-(4-fluoro-2-methylphenoxy)-N-(3-sulfamoylphenyl)benzamide,
4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)benzamide-
,
2,4-dichloro-6-(4-chloro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)benzamid-
e,
2,4-dichloro-6-(4-fluoro-2-methylphenoxy)-N-(3-sulfamoylphenyl)benzamid-
e,
2-(4-fluoro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)-4,6-bis(trifluorome-
thyl)benzamide,
2-(4-fluoro-2-methylphenoxy)-N-(3-sulfamoylphenyl)-4,6-bis(trifluoromethy-
l)benzamide,
5-chloro-2-(2-chloro-4-fluorophenoxy)-N-(3-sulfamoylphenyl)benzamide,
2-(4-fluoro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)-4-(trifluoromethoxy)b-
enzamide,
2-(4-fluoro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)-4-(trifluoro-
methyl)benzamide,
4,5-dichloro-2-(4-fluorophenoxy)-N-(3-sulfamoylphenyl)benzamide,
2-(4-fluoro-2-methoxyphenoxy)-4-(perfluoroethyl)-N-(3-sulfamoylphenyl)ben-
zamide,
5-fluoro-2-(4-fluoro-2-methylphenoxy)-N-(3-sulfamoylphenyl)benzami-
de,
2-(2-chloro-4-fluorophenoxy)-4-cyano-N-(3-sulfamoylphenyl)benzamide
or
N-(3-sulfamoylphenyl)-2-(4-(trifluoromethoxy)phenoxy)-4-(trifluoromethyl)-
benzamide.
(40) a combined Na.sub.V1.7 and Na.sub.V1.8 blocker, such as
DSP-2230 or BL-1021;
(41) a 5-HT3 antagonist, such as ondansetron;
(42) a TPRV 1 receptor agonist, such as capsaicin (NeurogesX.RTM.,
Qutenza.RTM.); and the pharmaceutically acceptable salts and
solvates thereof;
(43) a nicotinic receptor antagonist, such as varenicline;
(44) an N-type calcium channel antagonist, such as Z-160;
(45) a nerve growth factor antagonist, such as tanezumab;
(46) an endopeptidase stimulant, such as senrebotase;
(47) an angiotensin II antagonist, such as EMA-401;
In one embodiment, the additional appropriate therapeutic agents
are selected from V-116517, Pregabalin, controlled release
Pregabalin, Ezogabine (Potiga.RTM.). Ketamine/amitriptyline topical
cream (Amiket.RTM.), AVP-923, Perampanel (E-2007), Ralfinamide,
transdermal bupivacaine (Eladur.RTM.), CNV1014802, JNJ-10234094
(Carisbamate), BMS-954561 or ARC-4558.
In another embodiment, the additional appropriate therapeutic
agents are selected from
N-(6-amino-5-(2,3,5-trichlorophenyl)pyridin-2-yl)acetamide;
N-(6-amino-5-(2-chloro-5-methoxyphenyl)pyridin-2-yl)-1-methyl-1H-pyrazole-
-5-carboxamide; or
3-((4-(4-(trifluoromethoxy)phenyl)-1H-imidazol-2-yl)methyl)oxetan-3-amine-
.
In another embodiment, the additional therapeutic agent is a sodium
channel inhibitor (also know as a sodium channel blocker), such as
the Na.sub.V1.7 and Na.sub.V1.8 blockers identified above.
The amount of additional therapeutic agent present in the
compositions of this invention may be no more than the amount that
would normally be administered in a composition comprising that
therapeutic agent as the only active agent. The amount of
additional therapeutic agent in the presently disclosed
compositions may range from about 10% to 100% of the amount
normally present in a composition comprising that agent as the only
therapeutically active agent.
The compounds and salts of this invention or pharmaceutically
acceptable compositions thereof may also be incorporated into
compositions for coating an implantable medical device, such as
prostheses, artificial valves, vascular grafts, stents and
catheters. Accordingly, the invention, in another aspect, includes
a composition for coating an implantable device comprising a
compound or salt of the invention as described generally above, and
in classes and subclasses herein, and a carrier suitable for
coating said implantable device. In still another aspect, the
invention includes an implantable device coated with a composition
comprising a compound or salt of the invention as described
generally above, and in classes and subclasses herein, and a
carrier suitable for coating said implantable device. Suitable
coatings and the general preparation of coated implantable devices
are described in U.S. Pat. Nos. 6,099,562; 5,886,026; and
5,304,121. The coatings are typically biocompatible polymeric
materials such as a hydrogel polymer, polymethyldisiloxane,
polycaprolactone, polyethylene glycol, polylactic acid, ethylene
vinyl acetate, and mixtures thereof. The coatings may optionally be
further covered by a suitable topcoat of fluorosilicone,
polysaccarides, polyethylene glycol, phospholipids or combinations
thereof to impart controlled release characteristics in the
composition.
Another aspect of the invention relates to inhibiting Na.sub.V1.8
activity in a biological sample or a subject, which method
comprises administering to the subject, or contacting said
biological sample with a compound of the invention, a
pharmaceutically acceptable salt thereof, or a pharmaceutical
composition thereof. The term "biological sample," as used herein,
includes, without limitation, cell cultures or extracts thereof;
biopsied material obtained from a mammal or extracts thereof; and
blood, saliva, urine, feces, semen, tears, or other body fluids or
extracts thereof.
Inhibition of Na.sub.V1.8 activity in a biological sample is useful
for a variety of purposes that are known to one of skill in the
art. Examples of such purposes include, but are not limited to, the
study of sodium channels in biological and pathological phenomena;
and the comparative evaluation of new sodium channel
inhibitors.
EXAMPLES
General methods. .sup.1H NMR (400 MHz) spectra were obtained as
solutions in an appropriate deuterated solvent such as dimethyl
sulfoxide-d.sub.6 (DMSO-d.sub.6).
Compound purity, retention time, and electrospray mass spectrometry
(ESI-MS) data were determined by LC/MS analysis using one of two
methods: Method A and Method B.
LC/MS Method A. LC/MS analysis was conducted using a Waters Acquity
Ultra Performance LC system by reverse phase UPLC using an Acquity
UPLC BEH C18 column (30.times.2.1 mm, 1.7 .mu.m particle) made by
Waters (pn: 186002349), and a dual gradient run from 1-99% mobile
phase B over 1.2 minutes. Mobile phase A=H.sub.2O (0.05%
CF.sub.3CO.sub.2H). Mobile phase B=CH.sub.3CN (0.035%
CF.sub.3CO.sub.2H). Flow rate=1.5 mL/min, injection volume=1.5
.mu.L, and column temperature=60.degree. C.
LC/MS Method B. LC/MS analysis was conducted using a Waters Acquity
Ultra Performance LC system by reverse phase UPLC using an Acquity
UPLC BEH C18 column (50.times.2.1 mm, 1.7 .mu.m particle) made by
Waters (pn: 186002350), and a dual gradient run from 1-99% mobile
phase B over 3.0 minutes. Mobile phase A=H.sub.2O (0.05% CF3CO2H).
Mobile phase B=CH.sub.3CN (0.035% CF.sub.3CO.sub.2H). Flow rate=1.2
mL/min, injection volume=1.5 .mu.L, and column
temperature=60.degree. C.
Abbreviations
Unless otherwise noted, or where the context dictates otherwise,
the following abbreviations shall be understood to have the
following meanings:
TABLE-US-00001 Abbreviation Meaning NMR Nuclear magnetic resonance
MHz Megahertz DMSO Dimethyl sulfoxide ESI-MS Electrospray mass
spectrometry m/z Mass-to-Charge Ratio LC/MS Liquid chromatography-
mass spectrometry LC/MS-MS Liquid chromatography- tandem mass
spectrometry UPLC Ultra performance liquid chromatography mL
Milliliters min Minutes hr Hour .mu.L Microliters mm Millimeters
.mu.m Micrometers THF Tetrahydrofuran n-BuLi n-butyl lithium DCM
Dichloromethane T3P Propylphosphonic anhydride TEA triethylamine
2-MeTHF 2-methyltetrahydrofuran AcOH, HOAc Acetic acid DABCO
1,4-diazabicyclo[2.2.2]octane DCE 1,2-dichloroethane DMF
N,N-dimethylformamide Bu.sub.4NI Tetrabutylammonium iodide EtOAc
Ethyl acetate iPrOH Isopropyl alcohol g grams M Molar
(concentration) mmol millimoles mg milligrams N Normal
(concentration) aq Aqueous ppm Parts per million E-VIPR Electrical
stimulation voltage ion probe reader HEK Human embryonic kidney
KIR2.1 Inward-rectifier potassium ion channel 2.1 DMEM Dulbecco's
Modified Eagle's Medium FBS Fetal bovine serum NEAA Non-essential
amino acids HEPES 2-[4-(2-hydroxyethyl)
piperazin-1-yl]ethanesulfonic acid DiSBAC.sub.6(3)
Bis-(1,3-dihexyl-thiobarbituric acid) trimethine oxonol CC2-DMPE
Chlorocoumarin-2-dimyristoyl phosphatidylethanolamine VABSC-1
Voltage Assay Background Suppression Compound HS Human serum L
Liter(s) BSA Bovine Serum Albumin nL nanoliters ms millisecond Hz
Hertz nm nanometer NADPH Nicotinamide adenine dicnucleotide
phosphate, reduced form ACN Acetonitrile mM Millimolar
(concentration) .mu.M Micromolar (concentration) HPLC/MS/MS High
performance liquid chromatography/ tandem mass spectrometry IS
Internal standard HPLC High performance liquid chromatography MRM
Multiple reaction monitoring ESI Electrospray ionization LLOQ Lower
limit of quantitation AUC.sub.all Area under the plasma drug
concentration- versus-time curve from the time of drug
administration (time zero) to the last time point with measurable
drug concentration AUC.sub.0-.infin. Area under the plasma drug
concentration- versus-time curve from the time of drug
administration (time zero) extrapolated to time infinity C.sub.0
Concentration just after intravenous administration (at time zero)
Cl Clearance Vss Volume of distribution at steady state t.sub.1/2
Half-life SD Standard deviation % CV Coefficient of variation D5W
5% dextrose in water PK Pharmacokinetic rpm Revolutions per
minute
Example 1
2-(4-fluoro-2-methylphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-4-(trifluor-
omethyl)benzamide (10)
##STR00014##
A synthesis of
2-(4-fluoro-2-methylphenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-4-(trifluo-
romethyl)benzamide (10) is described in International Publication
No. WO 2014/120808 A9 and U.S. Publication No. 2014/0213616 A1,
both of which are incorporated by reference in their entirety.
Example 2
(4-(2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamido)-2-oxopyridi-
n-1(2H)-yl)methyl dihydrogen phosphate (20)
##STR00015##
A synthesis of
(4-(2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamido)-2-oxopyrid-
in-1(2H)-yl)methyl dihydrogen phosphate (20) is described in
International Publication No. WO 2015/089361 A1 and US Publication
No. 2015/0166589 A1, both of which are incorporated by reference in
their entirety.
Example 3
2-(4-fluoro-2-(methyl-d.sub.3)phenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)-4-
-(trifluoromethyl)benzamide (7)
##STR00016##
2-(4-fluoro-2-(methyl-d.sub.3)phenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)--
4-(trifluoromethyl)benzamide (7) was synthesized as shown in Scheme
1. Trideuteromethylation of 1-fluoro-4-methoxy-benzene (1) afforded
4-fluoro-1-methoxy-2-(methyl-d.sub.3)benzene (2), which underwent
demethylation to afford 4-fluoro-2-(methyl-d.sub.3)phenol (3).
Separately, coupling of 2-fluoro-4-(trifluoromethyl)benzoic acid
(4) with 2-methoxypyridin-4-amine afforded
2-fluoro-N-(2-methoxy-4-pyridyl)-4-(trifluoromethyl)benzamide (5),
which underwent demethylation to afford
2-fluoro-N-(2-oxo-1H-pyridin-4-yl)-4-(trifluoromethyl)benzamide
(6).
2-Fluoro-N-(2-oxo-1H-pyridin-4-yl)-4-(trifluoromethyl)benzamide (6)
was treated with 4-fluoro-2-(methyl-d.sub.3)phenol (3) in the
presence of base to afford
2-(4-fluoro-2-(methyl-d.sub.3)phenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)--
4-(trifluoromethyl)benzamide (7). Detailed experimental procedures
and analytical data are provided below.
##STR00017## ##STR00018## ##STR00019##
Preparation of 4-fluoro-2-(methyl-d.sub.3)phenol (3). To a solution
of 1-fluoro-4-methoxy-benzene (1) (1.02 g, 8.09 mmol) in THF (10
mL) at -10.degree. C. was added n-BuLi (2.38 g of 2.5 M in hexane,
8.75 mmol) over 20 minutes while maintaining internal temperature
below -5.degree. C. The solution was allowed to warm to room
temperature and then stirred for 1 hour. The mixture was cooled to
0.degree. C. and treated dropwise with iodomethane-d.sub.3 (1.30 g,
8.97 mmol, 99.5% D incorporation) while maintaining an internal
temperature under 5.degree. C. The reaction was allowed to come to
room temperature and stirred for 45 minutes. The reaction mixture
was diluted with diethyl ether and cold water, and the layers
separated. The aqueous layer was extracted with additional ether,
and the combined organic layers were washed with brine, dried over
sodium sulfate, filtered and concentrated. Silica gel
chromatography (0-10% ethyl acetate/hexane) provided
4-fluoro-1-methoxy-2-(methyl-d.sub.3)benzene (2) (160 mg, 14%).
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.03-6.97 (m, 1H), 6.95
(dd, J=8.4, 3.2 Hz, 1H), 6.90 (dd, J=8.9, 4.8 Hz, 1H), 3.76 (s, 3H)
ppm. LC/MS retention time (Method A): 0.60 minutes (1 minute
run).
To a solution of 4-fluoro-1-methoxy-2-(methyl-d.sub.3)benzene (2)
(160 mg, 1.12 mmol) in dichloromethane (2 mL) at 0.degree. C. was
added BBr.sub.3 (2.3 mL of 1 M in dichloromethane, 2.3 mmol)
dropwise over 5 minutes. The reaction was removed from the ice
bath, allowed to come to room temperature and stirred for 1 hour.
The reaction mixture was diluted with dichloromethane and washed
with water and brine. The organic layer was dried over sodium
sulfate, filtered and concentrated to provide crude
4-fluoro-2-(methyl-d.sub.3)phenol (3) (125 mg, 87%) which was used
directly in the next reaction. LC/MS retention time (Method A):
0.43 minutes (1 minute run).
Preparation of
2-fluoro-N-(2-oxo-1,2-dihydropyridin-4-yl)-4-(trifluoromethyl)benzamide
(6). A solution of 2-fluoro-4-(trifluoromethyl)benzoic acid (4)
(5.0 g, 24 mmol) in 2-methyltetrahydrofuran (30 mL) at 40.degree.
C. was treated with T3P solution (23 mL of 50% w/v in ethyl
acetate, 36 mmol) followed by pyridine (5.7 g, 5.8 mL, 72 mmol),
triethylamine (7.3 g, 10 mL, 72 mmol) and 2-methoxypyridin-4-amine
(3.3 g, 26 mmol). The reaction was heated at 40.degree. C. for 16
hours. Water (50 mL) was added and the mixture stirred. The
resulting layers were separated, and the organic layer was washed
with 50 mL 0.1 N HCl, 50 mL 10% KOH and 50 mL brine. The solution
was dried over sodium sulfate, filtered and evaporated to provide
2-fluoro-N-(2-methoxy-4-pyridyl)-4-(trifluoromethyl)benzamide (5)
(7.1 g, 94%). ESI-MS m/z calc. 314.07, found 315.2 (M+1)+. LC/MS
retention time (Method B): 1.21 minutes (3 minute run). .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 10.96 (s, 1H), 8.14-8.07 (m, 1H),
7.96-7.88 (m, 2H), 7.76 (dd, J=8.1, 1.6 Hz, 1H), 7.22 (d, J=4.7 Hz,
2H), 3.85 (s, 3H) ppm.
To a suspension of
2-fluoro-N-(2-methoxy-4-pyridyl)-4-(trifluoromethyl)benzamide (5)
(6.44 g, 20.5 mmol) in acetic acid (39 mL) was added HBr in acetic
acid (25 mL of 33% w/v, 103 mmol) and the reaction was stirred at
100.degree. C. for 16 hours. The reaction mixture was cooled to
28.degree. C. and treated with toluene (15 mL). The mixture was
stirred for 10 minutes, filtered, and the resulting solid washed
with toluene (15 mL) and dried under vacuum at 40.degree. C. to
provide 3.42 g of product. Second (0.35 g) and third (0.40 g) crops
of product were obtained by sequential filtration of the mother
liquor and rinsing the resulting solid with toluene (15 mL). The
solids were combined to obtain
2-fluoro-N-(2-oxo-1H-pyridin-4-yl)-4-(trifluoromethyl)benzamide (6)
(4.17 g, 70%). ESI-MS m/z calc. 300.05, found 301.1 (M+1)+. LC/MS
retention time (Method B): 1.05 minutes (3 minute run). .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.81 (br s, 1H), 10.86 (s, 1H),
7.96-7.87 (m, 2H), 7.76 (dd, J=8.2, 1.6 Hz, 1H), 7.48 (dd, J=7.1,
1.8 Hz, 1H), 6.96 (d, J=2.1 Hz, 1H), 6.56 (dd, J=7.2, 2.1 Hz, 1H)
ppm.
Preparation of
2-(4-fluoro-2-(methyl-d.sub.3)phenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)--
4-(trifluoromethyl)benzamide (7).
2-Fluoro-N-(2-oxo-1H-pyridin-4-yl)-4-(trifluoromethyl)benzamide (6)
(265 mg, 0.883 mmol), K.sub.2CO.sub.3 (366 mg, 2.645 mmol) and
4-fluoro-2-(methyl-d.sub.3)phenol (3) (125 mg, 0.968 mmol) were
combined in anhydrous DMSO (2.5 mL) and heated at 75.degree. C. for
16 hours. The reaction was diluted with water (10 mL), filtered,
and the resulting solid washed with water (10 mL) and air dried.
The solid was slurried in isobutyl acetate and filtered to provide
the desired product as an off-white solid (200 mg). The mother
liquor was concentrated and purified by silica gel chromatography
(1-15% methanol/dichloromethane) to provide an additional 60 mg of
product. The two crops were dissolved in dichloromethane, the
solvent concentrated and the resulting solid air dried to provide
2-(4-fluoro-2-(methyl-d.sub.3)phenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)--
4-(trifluoromethyl)benzamide (7) (260 mg, 72%). ESI-MS m/z calc.
409.11, found 410.2 (M+1).sup.+. LC/MS retention time (Method B):
1.59 minutes (3 minute run). .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.26 (s, 1H), 10.61 (s, 1H), 7.88-7.78 (m, 1H), 7.60 (dt,
J=8.1, 1.1 Hz, 1H), 7.31 (d, J=7.2 Hz, 1H), 7.22 (ddd, J=9.2, 2.5,
1.0 Hz, 1H), 7.12-7.07 (m, 2H), 6.97 (d, J=1.6 Hz, 1H), 6.75 (d,
J=2.0 Hz, 1H), 6.38 (dd, J=7.2, 2.1 Hz, 1H) ppm.
Example 4
(4-(2-(4-fluoro-2-(methyl-d.sub.3)phenoxy)-4-(trifluoromethyl)benzamido)-2-
-oxopyridin-1(2H)-yl)methyl dihydrogen phosphate (13)
##STR00020##
(4-(2-(4-fluoro-2-(methyl-d.sub.3)phenoxy)-4-(trifluoromethyl)benzamido)--
2-oxopyridin-1(2H)-yl)methyl dihydrogen phosphate (13) was
synthesized as shown in Scheme 2. Chloromethylation of
2-(4-fluoro-2-(methyl-d.sub.3)phenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)--
4-(trifluoromethyl)benzamide (7) with chloromethyl chloroformate
afforded
N-[1-(chloromethyl)-2-oxo-1,2-dihydropyridin-4-yl]-2-[4-fluoro-2-(methyl--
d3)phenoxy]-4-(trifluoromethyl)benzamide (11), which was then
treated with di-tert-butoxyphosphoryloxypotassium to afford
di-tert-butyl
((4-(2-(4-fluoro-2-(methyl-d.sub.3)phenoxy)-4-(trifluoromethyl)benzamido)-
-2-oxopyridin-1(2H)-yl)methyl) phosphate (12). Hydrolysis of
compound 12 afforded
(4-(2-(4-fluoro-2-(methyl-d3)phenoxy)-4-(trifluoromethyl)benzami-
do)-2-oxopyridin-1(2H)-yl)methyl dihydrogen phosphate (13).
Detailed experimental procedures and analytical data are provided
below.
##STR00021##
Preparation of
N-[1-(chloromethyl)-2-oxo-1,2-dihydropyridin-4-yl]-2-[4-fluoro-2-(methyl--
d3)phenoxy]-4-(trifluoromethyl)benzamide (11). To a slurry of
2-(4-fluoro-2-(methyl-d.sub.3)phenoxy)-N-(2-oxo-1,2-dihydropyridin-4-yl)--
4-(trifluoromethyl)benzamide (7) (1.9 g, 4.642 mmol) in DCE (20 mL)
and DMF (1 mL) was added DABCO (265 mg, 2.362 mmol). To the slurry
was added chloromethyl chloroformate (620 .mu.L, 6.972 mmol)
dropwise over 5 min. The mixture was stirred at 60.degree. C. for 1
hr. The light yellow slurry was cooled to ambient temperature and
diluted with water (50 mL) and DCM (50 mL). The organic phase was
separated and the aqueous phase was extracted with DCM (50 mL). The
combined organic phases were washed with brine. The organic phase
was dried over MgSO.sub.4, filtered over celite and concentrated
affording
N-[1-(chloromethyl)-2-oxo-1,2-dihydropyridin-4-yl]-2-[4-fluoro-2-(methyl--
d.sub.3)phenoxy]-4-(trifluoromethyl)benzamide (11) (2.1 g, 99%).
The product was used without further purification in the next step.
ESI-MS m/z calc. 457.08957, found 458.1 (M+1).sup.+; LC/MS
retention time (Method B): 2.06 minutes (3 minute run).
Preparation of di-tert-butyl
((4-(2-(4-fluoro-2-(methyl-d3)phenoxy)-4-(trifluoromethyl)benzamido)-2-ox-
opyridin-1(2H)-yl)methyl) phosphate (12). To a suspension of
N-[1-(chloromethyl)-2-oxo-1,2-dihydropyridin-4-yl]-2-[4-fluoro-2-(methyl--
d3)phenoxy]-4-(trifluoromethyl)benzamide (11) (2.1 g, 4.587 mmol)
in EtOAc (25 mL) was added tetrabutylammonium iodide (30 mg,
0.08122 mmol) followed by di-tert-butoxyphosphoryloxypotassium (1.3
g, 5.236 mmol) and the mixture heated to 70.degree. C. for 3 hr.
The reaction was quenched by pouring over ice water (50 mL) and
diluting with EtOAc (100 mL). The organic phase was separated and
washed with brine. The aqueous phases were extracted with EtOAc
(100 mL) and the combined organic phases were dried over
MgSO.sub.4, filtered and concentrated. The crude product was
purified using reverse phase chromatography (50-100% water/ACN)
affording di-tert-butyl
((4-(2-(4-fluoro-2-(methyl-d.sub.3)phenoxy)-4-(trifluoromethyl)benzamido)-
-2-oxopyridin-1(2H)-yl)methyl) phosphate (12) (1.75 g, 60%). ESI-MS
m/z calc. 631.21497, found 632.2 (M+1).sup.+; LC/MS retention time
(Method B): 2.25 minutes (3 minute run).
Preparation of
(4-(2-(4-fluoro-2-(methyl-d3)phenoxy)-4-(trifluoromethyl)benzamido)-2-oxo-
pyridin-1(2H)-yl)methyl dihydrogen phosphate (13). To a mixture of
di-tert-butyl
((4-(2-(4-fluoro-2-(methyl-d3)phenoxy)-4-(trifluoromethyl)benzamido)-2-ox-
opyridin-1(2H)-yl)methyl) phosphate (12) (1.5 g, 2.375 mmol) in
isopropanol (9 mL) and water (3 mL) was added HOAc (4.5 mL). The
mixture was heated at 70.degree. C. for 4.5 hr. The mixture was
concentrated to approximately 2 mL of oil and diluted with 10 mL
ACN affording a hazy solution which was further diluted with 10 mL
of isopropanol. The solvent was concentrated to approximately 2 mL
which afforded a granular solid. The solid was collected using a
medium fritted funnel and washed 3.times. with 5 mL of acetone. The
solid was air dried for 15 min, then in a vacuum oven at 40.degree.
C. for 16 hours affording
(4-(2-(4-fluoro-2-(methyl-d.sub.3)phenoxy)-4-(trifluoromethyl)benzamido)--
2-oxopyridin-1(2H)-yl)methyl dihydrogen phosphate (13) (150 mg,
12%). ESI-MS m/z calc. 519.0898, found 520.0 (M+1).sup.+; LC/MS
retention time (Method B): 1.99 minutes (3 minute run). .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.51 (s, 2H), 10.75 (s, 1H), 7.86
(d, J=7.9 Hz, 1H), 7.61 (dd, J=7.2, 1.7 Hz, 2H), 7.22 (ddd, J=9.3,
2.5, 1.0 Hz, 1H), 7.15-7.06 (m, 2H), 6.98 (d, J=1.5 Hz, 1H), 6.89
(d, J=2.3 Hz, 1H), 6.44 (dd, J=7.6, 2.3 Hz, 1H), 5.53 (d, J=9.7 Hz,
2H) ppm.
Example 5
Evaluation of Prodrug Conversion to Parent Compound: In Vitro
Hepatocyte Assay
Materials. Cryopreserved human hepatocytes and Cryopreserved
Hepatocytes Recovery Medium (CHRM.TM.) were purchased from Life
Technologies (Carlsbad, Calif.). Gibco.TM. Leibovitz's L-15 Medium
was purchased from Fisher Scientific (Waltham, Mass.).
Methods. 10 mM stock solutions containing Compound 20 and Compound
13 were prepared in DMSO. Equal volumes of the two 10 mM stock
solutions were mixed to form a combination stock solution
containing Compound 20 and Compound 13 in concentrations of 5 mM
each. The 5 mM combination stock solution was diluted to a
concentration of 50 .mu.M of each compound in DMSO ("50 .mu.M
combination stock"). Cryopreserved human hepatocytes were thawed in
CHRM.TM. medium and prepared as a suspension in incubation medium
(L-15 Medium with supplements containing glucose, HEPES buffer and
NaHCO.sub.3), with the final cell concentration of 0.625 million
cells/mL. In a 48 well plate, 1 .mu.L of the 50 .mu.M combination
stock and then 199 .mu.L of hepatocyte suspension (0.625 million
cells/mL) were added to each well. The plate was covered and
incubated at 37.degree. C. in an incubator with gentle shaking (50
rpm). The reactions were quenched at 0, 0.25, 0.5, 1 and 2 hours by
adding 200 .mu.L of ice-cold quench solution (ACN:MeOH:0.1% aqueous
formic acid, 2:2:1) containing internal standard (n=3 per time
point). The quenched samples were centrifuged, and the supernatants
were analyzed for the amount of Compound 20 and Compound 13
remaining, and the amount of Compound 10 and Compound 7 formed, by
LC-MS/MS analysis. LC-MS/MS analysis was conducted using a
Phenomenex Luna C8 column (3 micron, 2 mm diameter.times.30 mm
long, at room temperature) eluted with a gradient consisting of
mobile phases of 0.1% formic acid in water and 0.1% formic acid in
acetonitrile at a total flow rate of 0.6 mL/min and a total run
time of 4.5 minutes. The analytes were detected by MS/MS with
Electrospray Ionization (ESI) in the mode of multiple reaction
monitoring (MRM). The injection volume was 10 .mu.L.
Results. When the samples of Compound 20 and Compound 13 incubated
with human hepatocytes were analyzed by LC-MS/MS analysis, the
peaks corresponding to Compound 20 and Compound 13 decreased
quickly, with a concomitant increase in the peaks corresponding to
Compound 10 and Compound 7, indicating fast conversion of Compound
20 and Compound 13 to Compound 10 and Compound 7, respectively. The
t.sub.1/2 of Compound 20 and Compound 13 in human hepatocytes were
<0.5 hr. The percentages of Compound 20 and Compound 13
remaining at each time point during incubation with human
hepatocytes are reported in Table 1.
TABLE-US-00002 TABLE 1 Percentages of Compound 20 and Compound 13
Remaining during Hepatocyte Assay Time % Remaining % Remaining (hr)
(Compound 20) (Compound 13) 0 100 100 0.25 75.1 73.8 0.5 32.7 33.2
1 11.2 11.1 2 11.6 11.8
Example 6
E-VIPR Assay for Detecting and Measuring Na.sub.V Inhibition
Properties
Sodium ion channels are voltage-dependent proteins that can be
activated by inducing membrane voltage changes by applying electric
fields. The electrical stimulation instrument and methods of use,
referred to as E-VIPR, are described in International Publication
No. WO 2002/008748 A3 and C.-J. Huang et al. Characterization of
voltage-gated sodium channel blockers by electrical stimulation and
fluorescence detection of membrane potential, 24 Nature Biotech.
439-46 (2006), both of which are incorporated by reference in their
entirety. The instrument comprises a microtiter plate handler, an
optical system for exciting the coumarin dye while simultaneously
recording the coumarin and oxonol emissions, a waveform generator,
a current- or voltage-controlled amplifier, and parallel electrode
pairs that are inserted into assay plate wells. Under integrated
computer control, this instrument passes user-programmed electrical
stimulus protocols to cells within the wells of the microtiter
plate.
16-20 Hours prior to running the assay on E-VIPR, HEK cells
expressing human Na.sub.V 1.8 were seeded into 384-well plates
(Greiner #781091-1B), pre-coated with matrigel, at a density of
25,000 cells per well. 5% KIR2.1 Bacmam virus was added to the
final cell suspension before seeding into cell plates. HEK cells
were grown in DMEM media (exact composition is specific to each
cell type and Na.sub.V subtype) supplemented with 10% FBS (Fetal
Bovine Serum, qualified; Sigma #F4135), 1% NEAA (Non-Essential
Amino Acids, Life Tech #11140), 1% HEPES (Life Tech #15630), 1%
Pen-Strep (Penicillin-Streptomycin; Life Tech #15640) and 5
.mu.g/ml Blasticidin (Gibco #R210-01). Cells were expanded in
vented cap flasks, with 95% humidity and 5% CO.sub.2.
Reagents and Stock Solutions:
100 mg/mL Pluronic F-127 (Sigma #P2443), in dry DMSO
Compound Plates: Corning 384-well Polypropylene Round Bottom
#3656
Cell Plates: 384-well tissue culture treated plates. Greiner
#781091-1B
5% KIR 2.1 Bacmam virus (produced in-house), prepared as described
in Section 3.3 of J. A. Fornwald et al., Gene Expression in
Mammalian Cells Using BacMam, a Modified Baculovirus System, 1350
Methods in Molecular Biology 95-116 (2016), the entire contents of
which are incorporated by reference.
5 mM DiSBAC.sub.6(3) (a voltage sensitive oxonol acceptor) (Aurora
#00-100-010) in dry DMSO
5 mM CC2-DMPE (a membrane-bound coumarin phospholipid FRET donor)
(Aurora #00-100-008) in dry DMSO
89 mM VABSC-1 in H.sub.2O
Human Serum (HS, Millipore #S1P1-01KL, lot #2706671A)
Bath1 Buffer:
Sodium Chloride 160 mM (9.35 g/L), Potassium Chloride, 4.5 mM
(0.335 g/L), Glucose 10 mM (1.8 g/L), Magnesium Chloride
(Anhydrous) 1 mM (0.095 g/L), Calcium Chloride 2 mM (0.222 g/L),
HEPES 10 mM (2.38 g/L) in water.
Na/TMA Cl Bath1 Buffer:
Sodium Chloride 96 mM (5.61 g/L), Potassium Chloride 4.5 mM (0.335
g/L), Tetramethylammonium (TMA)-Cl 64 mM (7.01 g/L), Glucose 10 mM
(1.8 g/L), Magnesium Chloride (Anhydrous) 1 mM (0.095 g/L), Calcium
Chloride 2 mM (0.222 g/L) HEPES 10 mM (2.38 g/L) in water.
Hexyl Dye Solution (2.times.):
Bath1 Buffer containing 0.5% .beta.-cyclodextrin (made fresh prior
to each use, Sigma #C4767), 8 .mu.M CC2-DMPE and 2 .mu.M
DiSBAC.sub.6(3). The solution was made by adding 10% Pluronic F127
stock equal to combined volumes of CC2-DMPE and DiSBAC.sub.6(3).
The order of preparation was first mix Pluronic and CC2-DMPE, then
add DiSBAC.sub.6(3), then while vortexing add
Bath1/.beta.-Cyclodextrin.
Compound Loading Buffer (2.times.): Na/TMA Cl Bath1 Buffer
containing HS 50% (omitted in experiments run in the absence of
HS), VABSC-1 1 mM, BSA 0.2% (in Bath-1), KCl 9 mM, DMSO 0.75%.
Assay Protocol:
1) 400 nL of the test compound (Compound 7 or Compound 13) was
pre-spotted (in neat DMSO) into polypropylene compound plates at
400.times. desired final concentration, in an 11 point dose
response, 3-fold dilution, resulting in a top dose of 3 .mu.M final
concentration in the cell plate. Vehicle control (neat DMSO), and
positive control (Compound 10 (for assay with Compound 7) or
Compound 20 (for assay with Compound 13), 25 .mu.M final in assay
in DMSO) were added manually to the outermost columns of each plate
respectively. The compound plate was backfilled with 80 .mu.l per
well of Compound Loading Buffer resulting in a 400 fold dilution of
compound following a 1:1 transfer of compound into the cell plate
(Step 6). Final DMSO concentration for all wells in the assay was
0.625% (0.75% DMSO was supplemented to the Compound Loading Buffer
for a final DMSO concentration of 0.625%).
2) Hexyl Dye Solution was prepared.
3) Cell plates were prepared. On the day of the assay, the media
was aspirated, and the cells were washed three times with 80 .mu.L
of Bath-1 buffer, maintaining 25 .mu.L residual volume in each
well.
4) 25 .mu.L per well of Hexyl Dye Solution was dispensed into the
cell plates. The cells were incubated for 20 minutes at room temp
or ambient conditions in darkness.
5) 80 .mu.L per well of Compound Loading Buffer was dispensed into
compound plates.
6) The cell plates were washed three times with 80 .mu.L per well
of Bath-1 Buffer, leaving 25 .mu.L of residual volume. Then 25
.mu.L per well from compound plate was transferred to each cell
plate. The mixture was incubated for 30 minutes at room
temp/ambient conditions.
7) The plate was read on E-VIPR using the current-controlled
amplifier to deliver stimulation wave pulses using the following
protocol: 1.25 Amps, 2.5 ms pulse width biphasic waveform, 10 Hz
for 10 seconds at a scan rate of 200 Hz. A pre-stimulus recording
was performed for 0.5 seconds to obtain the un-stimulated
intensities baseline. The stimulatory waveform was followed by 0.5
seconds of post-stimulation recording to examine the relaxation to
the resting state.
Data Analysis:
Data were analyzed and reported as normalized ratios of emission
intensities measured in the 460 nm and 580 nm channels. The
response as a function of time was reported as the ratios obtained
using the following formula:
.function..times..times..times. ##EQU00001##
The data were further reduced by calculating the initial (R.sub.i)
and final (R.sub.f) ratios. These were the average ratio values
during part or all of the pre-stimulation period and during sample
points during the stimulation period. The fluorescence ratio
(R.sub.f/R.sub.i) was then calculated and reported as a function of
time.
Control responses were obtained by performing assays in the
presence of the positive control (Compound 10 or Compound 20), and
in the absence of pharmacological agents (DMSO vehicle negative
control). Responses to the negative (N) and positive (P) controls
were calculated as above. The compound antagonist % activity A was
then defined as:
.times. ##EQU00002## where X is the ratio response of the test
compound. Using this analysis method, dose response curves were
plotted and IC.sub.50 and Max % Activity values were generated.
Results:
The IC.sub.50 and Max % Activity values determined for Compound 7
and Compound 13 are reported in Tables 2 and 3, respectively.
TABLE-US-00003 TABLE 2 IC.sub.50 and Max % Activity of Compound 7
in E-VIPR Assay Nav1.8 IC.sub.50 (uM) Nav1.8 Max % Activity (%)
0.35 98
TABLE-US-00004 TABLE 3 IC.sub.50 and Max % Activity of Compound 13
in E-VIPR Assay Nav1.8 IC.sub.50 (uM) Nav1.8 Max % Activity (%) 1.2
99
Example 7
Evaluation of Metabolic Stability: In Vitro Microsomal Assay
Materials. Rat, Dog, Monkey and Human liver microsomes (20 mg/mL)
were obtained from Xenotech, LLC (Lenexa, Kans.). P-nicotinamide
adenine dinucleotide phosphate, reduced form (NADPH), magnesium
chloride (MgCl.sub.2), and dimethyl sulfoxide (DMSO) were purchased
from Sigma-Aldrich.
Methods. 10 mM stock solutions containing the test compound
(Compound 10 or Compound 7) were prepared in DMSO. The 10 mM stock
solutions were diluted to 100 .mu.M in DMSO. In each cluster
polypropylene tube, 190.7 .mu.L of 100 mM phosphate buffer, pH 7.4
was added, then 2.5 .mu.L of liver mocrosomes (20 mg/mL, rat, dog,
monkey or human) was added, then a 2 .mu.L aliquot of the 100 .mu.M
test compound was added, and the mixture was pre-warmed for 10
minutes. Reactions were initiated by addition of 4.8 .mu.L of
pre-warmed NADPH solution (100 mM in 100 mM phosphate buffer). The
final reaction volume was 200 .mu.L and contained 0.25 mg/mL rat,
dog, monkey or human liver microsomes, 1.0 .mu.M test compound, and
2.4 mM NADPH in 0.1 M potassium phosphate buffer, pH 7.4. The
reaction mixtures were incubated at 37.degree. C., and the
reactions were quenched at 0, 15, 30 and 60 minutes by adding 200
.mu.L of ice-cold quench solution (ACN:MeOH:0.1% formic acid in
water 2:2:1) containing internal standard, n=3 per time point. The
tubes were centrifuged and supernatants were analyzed for amounts
of the test compound remaining by LC-MS/MS. The HPLC system
included a Phenomenex Luna C8 column, 3 micron, 2 mm
diameter.times.30 mm long eluted with a gradient mobile phase
consisting of 0.1% formic acid in water or in acetonitrile. The
analytes were detected by MS/MS with Electrospray Ionization (ESI)
in the mode of multiple reaction monitoring (MRM). The injection
volume was 10 .mu.L.
Results. The percentages of Compounds 7 and 10 remaining at each
time point during incubation with rat, dog, monkey, and human liver
microsomes are reported in FIGS. 1 (rat), 2 (dog), 3 (monkey), and
4 (human) The data is also reported below in Tables 4a (rat), 4b
(dog), 4c (monkey) and 4d (human)
TABLE-US-00005 TABLE 4a Rat liver microsome data for Compounds 7
and 10 Compound 10 Compound 7 Time (% remaining) (% remaining) 0
min 100 100 15 min 108 109 30 min 102 105 60 min 87.4 92.2
TABLE-US-00006 TABLE 4b Dog liver microsome data for Compounds 7
and 10 Compound 10 Compound 7 Time (% remaining) (% remaining) 0
min 100 100 15 min 85.9 86.1 30 min 85.4 85.8 60 min 85.7 87.5
TABLE-US-00007 TABLE 4c Monkey liver microsome data for Compounds 7
and 10 Compound 10 Compound 7 Time (% remaining) (% remaining) 0
min 100 100 15 min 96.4 97.0 30 min 92.4 93.3 60 min 91.4 92.5
TABLE-US-00008 TABLE 4d Human liver microsome data for Compounds 7
and 10 Compound 10 Compound 7 Time (% remaining) (% remaining) 0
min 100 100 15 min 110 109 30 min 105 105 60 min 106 106
Example 8
In Vivo Pharmacokinetic Study
General Procedures. Concentrations of the test compounds in plasma
were determined using a high performance liquid
chromatography/tandem mass spectrometry (HPLC/MS/MS) method. The
test compounds along with the internal standard (IS) were extracted
from plasma (20 .mu.L) by direct protein precipitation with
acetonitrile (1:25 ratio of plasma/acetonitrile). After
centrifugation, the supernatant extract (10 .mu.L) was injected
onto the LC/MS/MS system. The HPLC system included a Phenomenex
Luna C8 column, 3 micron, 2 mm diameter.times.30 mm long eluted
with a gradient mobile phase consisting of 0.1% formic acid in
water or in acetonitrile. The analytes were detected by MS/MS with
Electrospray Ionization (ESI) in the mode of multiple reaction
monitoring (MRM). The lower limit of quantitation (LLOQ) was 1.00
ng/mL. The linear range of the assay was from 1 to 3000 ng/mL. The
assay accuracy was within 20% of the nominal values.
Samples of the cassette dose formulation of the test compounds were
assayed with similar HPLC/MS/MS method after dilution first with
DMSO and then with blank plasma, with final dilution factor of
1000-fold.
Plasma concentration-time profiles of the test compounds were
analyzed by noncompartmental pharmacokinetic methods using PK
module in Watson, Version 7.4.2 (Thermo Scientific).
Pharmacokinetic parameters including AUC.sub.a11,
AUC.sub.0-.infin., C.sub.0, Cl, Vss and t.sub.1/2 were
determined.
Descriptive statistical data of plasma concentrations and
pharmacokinetic parameter estimates were calculated, including the
mean, standard deviation (SD), and coefficient of variation (% CV)
using Microsoft Excel 2010.
Rat IV Study. Compounds 7 and 10 were administered simultaneously
in a single intravenous bolus to Male Sprague Dawley rats (n=3) via
jugular cannula. The nominal dose of each compound was 0.5 mg/kg.
The cassette dosing solution was formulated in D5W with additives
Animals had free access to food and water before and after dosing.
Blood samples (approximately 0.25 mL each) were collected via a
carotid artery catheter prior to dosing and at 0 (predose), 5 min,
10 min, 0.25, 0.5, 1, 2, 4, 8, 12, 24 hours post dose. Each blood
sample was collected into a tube that was kept on wet ice and
contained potassium EDTA as the anticoagulant. Plasma was separated
and stored at approximately -70.degree. C. until analysis.
Plasma samples and dosing solutions were analyzed using a liquid
chromatography/tandem mass spectrometry (LC/MS/MS) method to
determine the concentrations of Compounds 7 and 10 with a lower
limit of quantitation (LLOQ) of 1.00 ng/mL. The average plasma
concentrations of Compounds 7 and 10 are plotted in FIG. 5 and are
also presented in tabular form in Table 5.
TABLE-US-00009 TABLE 5 Rat IV, plasma concentrations (ng/mL) versus
time (hours) Compound 10 Compound 7 Time (hours) (ng/mL) (ng/mL)
0.083 391 420 0.167 349 399 0.25 316 371 0.5 239 301 1 174 256 2
111 208 4 51.6 154 8 14.3 91.3 12 4.27 47.6 24 7.57
Plasma concentration vs. time data were subjected to
noncompartmental pharmacokinetic (PK) analysis. The results of this
analysis are provided in Table 6. Measured doses of Compounds 7 and
10 are also reported in Table 6. To determined the measured dose of
each compound, the dose formulation (50 .mu.L) was aliquoted into a
cluster tube at the time of dosing. Then 450 .mu.L of DMSO was
added to the tube to dilute it 10.times.. Then the diluted dosing
solution was spiked into rat blank plasma with 100.times. dilution.
The resulting plasma sample was analyzed along with the plasma
samples collected from rats that were dosed with the compounds,
using the same LC/MS/MS method.
TABLE-US-00010 TABLE 6 Pharmacokinetic Data from Rat IV Study
Measured Dose Dose AUC.sub.all AUC.sub.0-.infin. Cl (ml/ (mg/kg)
(mg/kg) Analyte C.sub.0 (ug/ml) (ug*hr/ml) (ug*hr/ml) t.sub.1/2
(hr) min/kg) Vss (L/kg) 0.5 0.560 10 0.245 0.415 0.422 2.2 22.1 3.4
0.5 0.464 7 0.211 0.937 0.961 4.4 8.07 3.0
As shown in Table 6, Compound 7 has a lower clearance and a longer
t.sub.1/2 than Compound 10 in rats.
Many modifications and variations of the embodiments described
herein may be made without departing from the scope, as is apparent
to those skilled in the art. The specific embodiments described
herein are offered by way of example only.
* * * * *
References